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LISINOPRIL 2.5MG, 5MG, 10MG & 20MG TABLETS 
(LISINOPRIL DIHYDRATE) 
PL 20092/0008, 0009, 0010 & 0011 
 
 
LAY SUMMARY 
 
 
The Medicines and Healthcare products Regulatory Agency (MHRA) granted Lupin 
(Europe) Limited Marketing Authorisations (licences) for the medicinal products 
Lisinopril 2.5mg Tablets (PL 20092/0008), Lisinopril 5mg Tablets (PL 20092/0009), 
Lisinopril 10mg Tablets (PL 20092/0010), and Lisinopril 20mg Tablets (PL 
20092/0011) on 20
th June 2007. These are prescription-only medicines (POM) used 
for the treatment of high blood pressure, heart failure, kidney problems related to 
diabetes and high blood pressure, and after a heart attack to slow down weakening of 
your heart. 
 
Lisinopril Tablets contain the active ingredient lisinopril. It acts by widening your 
blood vessels, which helps reduce your blood pressure and makes it easier for your 
heart to pump blood to all parts of the body. 
 
The test products were considered to be the same as the reference products Zestril 
Tablets 2.5mg, 5mg, 10mg and 20mg respectively (PL 17901/0060, 0061, 0062 & 
0063, AstraZeneca UK Limited) based on the data submitted by Lupin (Europe) 
Limited. 
 
No new or unexpected safety concerns arose from these applications and it was 
therefore judged that the benefits of taking Lisinopril 2.5mg, 5mg, 10mg and 20mg 
Tablets outweigh the risk; hence Marketing Authorisations have been granted. 
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INTRODUCTION 
 
Based on the review of the data on quality, safety and efficacy, the MHRA granted 
Lupin (Europe) Limited Marketing Authorisations for the medicinal products 
Lisinopril 2.5mg Tablets (PL 20092/0008), Lisinopril 5mg Tablets (PL 20092/0009), 
Lisinopril 10mg Tablets (PL 20092/0010), and Lisinopril 20mg Tablets (PL 
20092/0011) on 20
th June 2007. The products are prescription-only medicines. 
 
These are abridged, standard, national applications for Lisinopril 2.5mg, 5mg, 10mg 
and 20mg Tablets. These are four strengths of lisinopril, submitted under Article 10.1 
of Directive 2001/83/EC, as amended, claiming to be generic medicinal products of 
the reference products, Zestril Tablets 2.5mg, 5mg, 10mg and 20mg respectively (PL 
17901/0060, 0061, 0062 & 0063), granted to AstraZeneca UK Limited on 8
th June 
2000. These reference products were originally granted as PL 00029/0208, 0204, 
0205 and 0206 respectively, authorised to Imperial Chemical Industries on 1
st July 
1993. The reference products have been authorised in the EEA for more than 10 
years, so the period of data exclusivity has expired. 
 
Lisinopril Tablets contain the active ingredient lisinopril, as lisinopril dihydrate, 
which belongs to a group of medicines called Angiotensin Converting Enzyme (ACE) 
inhibitors. The mechanism through which lisinopril lowers blood pressure is believed 
to be primarily suppression of the renin-angiotensin-aldosterone system. Lisinopril 
inhibits the angiotensin converting enzyme (ACE) that catalyses the conversion of 
angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also 
stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in 
decreased concentrations of angiotensin II which results in decreased vasopressor 
activity and reduced aldosterone secretion. 
 
Lisinopril Tablets are used for the treatment of essential and renovascular 
hypertension; treatment of symptomatic heart failure; short-term treatment of 
haemodynamically stable patients following acute myocardial infarction; and 
treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and 
incipient nephropathy. The dose of losartan potassium to be used in these indications 
ranges from 2.5 to 80 mg daily. 
 
These applications for Lisinopril 2.5mg, 5mg, 10mg and 20mg Tablets were 
submitted at the same time and they all depend on the single bioequivalence study 
presented comparing the applicant’s 20mg product with the AstraZeneca reference 
product Zestril Tablets 20mg, sourced from France. Consequently, all sections of the 
Scientific Discussion refer to all four products. As the test products, Lisinopril 2.5mg, 
5mg, 10mg and 20mg, were deemed to meet the criteria specified in the Note for 
Guidance on the investigation of bioavailability and bioequivalence 
(CPMP/EWP/QWP/1401/98), the results and conclusions of the bioequivalence study 
on the 20mg strength were extrapolated to the other tablet strengths. 
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PHARMACEUTICAL ASSESSMENT 
 
 ACTIVE  SUBSTANCE 
 Lisinopril  dihydrate 
Nomenclature: 
INN:    Lisinopril  dihydrate 
Chemical name:  (2S) - 1- [(2S)-6-amino -2- [ [ (1S) – 1 – carboxy – 3 - 
phenylpropyl] amino] hexanoyl] pyrrole – 2 - carboxylic acid 
Structure: 
 
 
 
Molecular formula:   C21H31N3O5,2H2O 
Molecular weight:  441.5 
CAS No:    103577-45-3 
Physical form:   White to off white powder 
Solubility:  Lisinopril dihydrate is soluble in water, sparingly soluble in 
methanol, and practically insoluble in acetone and in ethanol 
 
The active substance, lisinopril dihydrate, is the subject of a European Pharmacopoeia 
(EP) monograph. 
 
All aspects of the manufacture and control of lisinopril dihydrate are supported by an 
EDQM Certificate of Suitability. This certificate is accepted as confirmation of the 
suitability of lisinopril dihydrate for inclusion in this medicinal product. 
 
Appropriate stability data have been generated for the active substance stored in the 
proposed commercial packaging. These data demonstrate the stability of the active 
substance and support a retest period of 48 months when stored in the proposed 
packaging. 
 
  DRUG PRODUCT  
Description and Composition 
The drug products are presented as round, biconvex, uncoated tablets with a scoreline 
on one side and a number representing the strength of the tablet on the other side. The 
tablets contain 2.5mg, 5mg, 10mg or 20mg of the active ingredient lisinopril, as 
lisinopril dihydrate. 
 
Other ingredients consist of pharmaceutical excipients, namely mannitol, calcium 
hydrogen phosphate, maize starch, pregelatinised starch, colloidal anhydrous silica, 
and magnesium stearate. In addition, the 5mg, 10mg and 20mg strength tablets 
contain the excipient red iron oxide (E172). Appropriate justification for the inclusion 
of each excipient has been provided. 
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All excipients used comply with their respective European Pharmacopoeia 
monographs, with the exception of red iron oxide (E172) which complies with a 
satisfactory in-house specification. Satisfactory Certificates of Analysis have been 
provided for all excipients. 
 
The magnesium stearate has been specified as being of vegetable origin. There are no 
materials of human or animal origin contained in or used in the manufacturing process 
for the proposed product. 
 
There were no novel excipients used and no overages. 
 
Dissolution profiles 
Dissolution profiles for the drug products were found to be similar to those for the 
reference products. 
 
Pharmaceutical development 
Details of the pharmaceutical development of the drug products have been supplied 
and are satisfactory. 
 
Manufacture 
A description and flow-chart of the manufacturing method has been provided. 
 
In-process controls have been provided and are appropriate considering the nature of 
the product and the method of manufacture. Process validation studies have been 
conducted and are satisfactory. 
 
Finished product specification 
The finished product specification covering the 4 strengths is satisfactory. Acceptance 
limits have been justified with respect to conventional pharmaceutical requirements 
and, where appropriate, safety. Test methods have been described and have been 
adequately validated, as appropriate. Batch data have been provided and comply with 
the release specification. Certificates of Analysis have been provided for any working 
standards used. 
 
Container Closure System 
The tablets are packed in PVC (polyvinyl chloride) / PVDC (polyvinylidene chloride) 
/ aluminium foil blisters, which are placed with the Patient Information Leaflet (PIL) 
into cardboard outer cartons. The products are packaged in pack sizes of 28 tablets. 
 
Specifications and Certificates of Analysis for all packaging components used have 
been provided. These are satisfactory. 
 
All primary product packaging complies with EU legislation, Directive 2002/72/EC 
(as amended), and is suitable for contact with foodstuffs. 
 
Stability 
Finished product stability studies have been conducted in accordance with current 
guidelines and results were within the proposed specification limits. Based on the 
results, a shelf-life of 36 months has been set, which is satisfactory. Storage 
conditions are “Store below 25°C” and “Store in the original package”. UKPAR Lisinopril 2.5mg, 5mg, 10mg & 20mg Tablets  PL 20092/0008-11 
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Bioequivalence Study 
A single bioequivalence study was submitted comparing the test product, Lisinopril 
20mg Tablets, to the reference product, Zestril Tablets 20mg (AstraZeneca Reims). 
 
An evaluation of the bioequivalence study is found in the Clinical Assessment section. 
 
Product Information 
The approved SmPCs, leaflet, and labelling are satisfactory. 
 
Conclusion 
The test products are pharmaceutically equivalent to the reference products which 
have been licensed in the UK for over 10 years. The drug products correspond to the 
current EU definition of a generic medicinal product because they comply with the 
criteria of having the same qualitative and quantitative composition in terms of the 
active substance and pharmaceutical form. On this basis, and considering the 
bioequivalence data provided, the applicant’s claim that Lisinopril 20mg Tablets is a 
generic medicinal product of Zestril Tablets 20mg appears justified. As the test 
products, Lisinopril 2.5mg, 5mg, 10mg and 20mg, meet all the criteria as specified in 
the Note for Guidance on the investigation of bioavailability and bioequivalence 
(CPMP/EWP/QWP/1401/98), the results and conclusions of the bioequivalence study 
on the 20mg strength were extrapolated to the 2.5mg, 5mg and 10mg strength tablets. 
 
All pharmaceutical issues have been resolved and the quality grounds for these 
applications are considered adequate. It is recommended that Marketing 
Authorisations are granted. 
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PRECLINICAL ASSESSMENT 
 
These abridged applications, submitted under Article 10.1 of Directive 2001/83/EC, 
as amended, are for Lisinopril 2.5mg, 5mg, 10mg and 20mg Tablets, products 
claiming to be generic medicinal products of Zestril Tablets 2.5mg, 5mg, 10mg and 
20mg (AstraZeneca UK Limited) respectively, which have been licensed within the 
EEA for over 10 years.  
 
No new preclinical data have been supplied with these applications and none are 
required for applications of this type. 
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CLINICAL ASSESSMENT 
 
INDICATIONS 
Lisinopril 2.5mg, 5mg, 10mg and 20mg Tablets are indicated for: 
 
•  Treatment of essential and renovascular hypertension.  
•  Treatment of symptomatic heart failure.  
•  Short-term treatment of haemodynamically stable patients following acute 
myocardial infarction. 
•  Treatment of renal disease in hypertensive patients with Type 2 diabetes 
mellitus and incipient nephropathy. 
 
The indications are consistent with those for the innovator product and are 
satisfactory. 
 
POSOLOGY AND METHOD OF ADMINISTRATION 
The posology is consistent with that for the innovator product. 
 
TOXICOLOGY  
No new data have been submitted and none are required for this type of application. 
 
CLINICAL PHARMACOLOGY 
Pharmacodynamics 
No new pharmacodynamic data are presented and none are required. 
 
Pharmacokinetics - Bioequivalence study 
Only one bioequivalence study, using 20 mg tablets, has been submitted to cover all 
four tablet strengths. According to the Note for Guidance on the investigation of 
bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98), this may be 
acceptable if the following conditions are fulfilled: 
 
•  The pharmaceutical products are manufactured by the same manufacturer and 
process; 
•  The drug input has been shown to be linear over the therapeutic dose range; 
•  The qualititative composition of the different strengths is the same; 
•  The ratio between amounts of active substance and excipients is the same or, 
in the case of preparations containing a low concentration of active substance 
(less than 5%) the ratio between the amounts of excipients is similar 
•  The dissolution profile is similar under identical conditions for all strengths.  
 
As the test products were deemed to meet the criteria specified in the Note for 
Guidance, the results and conclusions of the bioequivalence study on the 20mg 
strength were extrapolated to the 2.5mg, 5mg and 10mg tablet strengths. 
 
The applicant presented a single bioequivalence study comparing the test product, 
Lisinopril 20mg Tablets, to the reference product, Zestril Tablets 20mg (AstraZeneca 
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sequence, single dose, crossover study conducted in healthy human adult male 
subjects under fasting conditions. 
 
36 volunteers were recruited to the study. Only 32 subjects completed the study: one 
subject was withdrawn during the first period due to giddiness and hypotension, 
requiring intravenous fluids; two subjects failed to attend for the second period and 
one subject chose to withdraw before the second period. The Period 1 data for the last 
three of these subjects were included in analysis. Statistical analysis was performed on 
data from 31 subjects (one subject was excluded from statistical analysis). 
 
A single oral dose of each drug was administered with an 8-day washout between 
dosing periods. Subjects were randomised to order of dosing. In each period, subjects 
were institutionalised from the evening before to 36 hours after dosing and were to 
return at 48 hours post-dosing for blood sampling. Subjects were fasted from 10 hours 
prior to dosing and appropriate restrictions on diet, fluid intake and concomitant 
medications were maintained.  
 
Blood samples were taken at intervals appropriate to the known pharmacokinetic 
profile of the drug up to 48 hours after dosing and analysed for lisinopril 
concentration. The following pharmacokinetic parameters were reported: AUC(0-inf), 
Cmax, AUC(0-t), Tmax, T1/2 and Kel. Analysis of variance was conducted using subject, 
period, sequence and treatment as variables. 90% confidence intervals (CI) for the 
ratio of the least square means of the log-transformed values were presented and 
compared to the accepted range set down in CPMP/EWP/QWP/1401/98. 
 
Biostudy Results: 
 
   C max 
(ng/mL) 
AUC0-t 
(ng.hr/mL) 
AUC0-∞ 
(µ=ng.hr/mL) 
Tmax(h) 
(mean) 
Test  formulation  31  30 30 31  N 
Reference 
formulation 
31  31 31 31 
Test formulation  105.333  1443.074  1488.612  6.58  Mean 
Reference 
formulation 
106.989 1453.694  1494.676  6.10 
Test formulation  39.201  513.776  511.757  1.53  SD 
Reference 
formulation 
43.661 537.032  534.424  0.97 
Test  formulation  37.22  35.60 34.38 23.22  C.V. (%) 
Reference 
formulation 
40.81  36.94 35.76 15.91 
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A summary of the results is represented below for log-transformed data: 
 
Summary of comparative bioavailability - lisinopril 
 
Parameter 
(units) 
LSM for test 
product 
LSM for reference  Ratio (%)  90% CI 
(parametric, %) 
lnCmax (ng/ml)  97.92+39.20 96.90+43.66 101.32 90.24-113.76 
lnAUC(0 - t) 
(ng/h/ml) 
1336.77+513.78 1344.58+537.03 101.10  90.28-113.21 
lnAUC(0-inf) 
(ng/h/ml) 
1388.34+511.75 1390.18+534.42 101.51  91.10-113.12 
 
Overall conclusions on pharmacokinetics 
The 90% confidence intervals for the ratio of the geometric means of the log-
transformed values for AUC(0-inf), Cmax and AUC(0-t) was within the accepted 80-125% 
bioequivalence range for lisinopril. Bioequivalence was thus demonstrated for the 
20mg tablet strength. 
 
EFFICACY 
Efficacy is reviewed in the Clinical Expert Report. The reference products are 
established and the applications depend upon the ability to demonstrate 
bioequivalence. 
 
No new efficacy data are required. The applicant has submitted a satisfactory 
literature review. 
 
SAFETY 
Safety is reviewed in the Clinical Expert Report.  
 
No new safety data were submitted and none are required for these types of 
applications. The reference products are established and the main basis of the 
applications depends upon the bioequivalence study. The applicant has submitted a 
satisfactory literature review confirming the safety of lisinopril tablets. No new safety 
issues have been detected. 
 
EXPERT REPORT 
A satisfactory expert report is provided, and has been prepared by an appropriately 
qualified expert. An appropriate CV for the expert has been supplied. 
 
PRODUCT INFORMATION: 
Summary of Product Characteristics  
The approved SmPCs are consistent with those for the innovator products and are 
acceptable. 
 
Patient Information Leaflet 
The PIL is in line with the approved SmPCs and is satisfactory. 
 
Labelling 
Colour mock-ups of the labelling have been provided. The labelling is satisfactory and 
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CONCLUSIONS  
All issues have been adequately addressed by the applicant. The bioequivalence study 
was of an appropriate design and bioequivalence of the 20mg strength test and 
reference products was shown with 90% Confidence Intervals within general 
acceptance limits. The conditions, as detailed in CPMP/EWP/QWP/1401/98, for a 
single bioequivalence study to cover multiple strengths of a product have been met, so 
the results and conclusions of this bioequivalence study were extrapolated to the 
2.5mg, 5mg and 10mg strength tablets. 
 
Sufficient clinical information has been submitted to support these applications. When 
used as indicated, lisinopril has a favourable benefit-to-risk ratio. Marketing 
Authorisations may be granted on medical grounds. 
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OVERALL CONCLUSION AND RISK BENEFIT ASSESSMENT 
 
QUALITY 
The important quality characteristics of Lisinopril 2.5mg, 5mg, 10mg and 20mg 
Tablets are well defined and controlled. The specifications and batch analytical results 
indicate consistency from batch to batch. There are no outstanding quality issues that 
would have a negative impact on the benefit/risk balance. 
 
PRECLINICAL 
No new preclinical data were submitted and none are required for applications of this 
type. 
 
EFFICACY 
Bioequivalence has been demonstrated between the applicant’s Lisinopril 20mg 
Tablets, and the reference product Zestril Tablets 20mg (AstraZeneca Reims). As the 
test products were deemed to meet the criteria specified in the Note for Guidance on 
the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98), 
the results and conclusions of the bioequivalence study on the 20mg strength were 
extrapolated to the 2.5mg, 5mg and 10mg tablet strengths. Thus, no separate 
bioequivalence studies were necessary for these strengths. 
 
No new or unexpected safety concerns arise from these applications. 
 
PRODUCT LITERATURE 
The SmPCs, PIL and labelling are satisfactory and consistent with those for Zestril 
Tablets 2.5mg, 5mg, 10mg and 20mg. 
 
A package leaflet has been submitted to the MHRA along with results of consultations 
with target patient groups ("user testing"), in accordance with Article 59 of Council 
Directive 2001/83/EC. The results indicate that the package leaflet is well-structured 
and organised, easy to understand and written in a comprehensive manner. The test 
shows that the patients/users are able to act upon the information that it contains.  
 
The approved labelling artwork complies with statutory requirements. In line with 
current legislation, the name of the product in Braille appears on the outer packaging 
and sufficient space has been included for a standard UK pharmacy dispensing label. 
 
RISK BENEFIT ASSESSMENT 
The quality of the products is acceptable and no new preclinical or clinical safety 
concerns have been identified. The bioequivalence study and the valid extrapolation 
of its results and conclusions support the claim that the applicant’s products and their 
respective reference products are interchangeable. Extensive clinical experience with 
lisinopril dihydrate is considered to have demonstrated the therapeutic value of the 
active substance. The risk: benefit is, therefore, considered to be positive. 
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LISINOPRIL 2.5MG, 5MG, 10MG & 20MG TABLETS 
(LISINOPRIL DIHYDRATE) 
PL 20092/0008, 0009, 0010 & 0011 
 
 
 
STEPS TAKEN FOR ASSESSMENT 
 
 
1  The MHRA received the marketing authorisation applications on 12
th October 
2005 
 
2  Following standard checks and communication with the applicant the MHRA 
considered the applications valid on 3
rd November 2005 
 
3  Following assessment of the applications the MHRA requested further 
information relating to the quality dossiers on 14
th June 2006, and further 
information relating to the clinical dossiers on 26
th July 2006 
 
4  The applicant responded to the MHRA’s requests, providing further information 
for the clinical sections on 1
st February 2007 and further information for the 
quality sections on 2
nd February 2007 
 
5 
 
Following assessment of the response the MHRA requested further information 
relating to the quality sections on 13
th February 2007 and 24
th April 2007 
 
6 
 
The applicant responded to the MHRA’s request, providing further information 
for the quality sections on 12
th April 2007 and 30
th April 2007 respectively 
 
7  The applications were determined on 20
th June 2007 
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LISINOPRIL 2.5MG, 5MG, 10MG & 20MG TABLETS 
(LISINOPRIL DIHYDRATE) 
PL 20092/0008, 0009, 0010 & 0011 
 
 
 
STEPS TAKEN AFTER AUTHORISATION 
 
 
Date 
submitted 
  
Application type  Scope  Outcome 
20/12/2007 Variation 
Pharmaceutical 
Type 1B National 
To change the shelf life 
of the finished product 
from 2 years to 3 years. 
 
This variation was 
submitted for all 4 PLs. 
 
Application granted 
20/12/2007 
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SUMMARY OF PRODUCT CHARACTERISTICS 
The UK Summary of Product Characteristics (SPC) for Lisinopril 2.5mg Tablets is as 
follows: 
 
1  NAME OF THE MEDICINAL PRODUCT 
Lisinopril 2.5 mg tablets. 
 
2  QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each uncoated tablet contains Lisinopril Dihydrate equivalent to 2.5 mg of anhydrous 
Lisinopril.  
For a full list of excipients, see section 6.1. 
 
3 PHARMACEUTICAL  FORM 
Tablet 
White, round tablets marked ‘2.5’on one side and scoreline on other side. 
The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal 
doses. 
 
4 CLINICAL  PARTICULARS 
4.1 THERAPEUTIC  INDICATIONS 
Hypertension 
Treatment of hypertension.  
Heart failure 
Treatment of symptomatic heart failure.  
Acute myocardial infarction 
Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an 
acute myocardial infarction.  
Renal complications of diabetes mellitus 
Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient 
nephropathy (see section 5.1).  
 
4.2  POSOLOGY AND METHOD OF ADMINISTRATION 
Lisinopril should be administered orally in a single daily dose. As with all other medication 
taken once daily, Lisinopril should be taken at approximately the same time each day. The 
absorption of Lisinopril tablets is not affected by food.  
The dose should be individualised according to patient profile and blood pressure response 
(see section 4.4).  
Hypertension 
Lisinopril may be used as monotherapy or in combination with other classes of 
antihypertensive therapy.  
Starting dose 
In patients with hypertension the usual recommended starting dose is 10 mg. Patients with a 
strongly activated renin-angiotensin-aldosterone system (in particular, renovascular 
hypertension, salt and /or volume depletion, cardiac decompensation, or severe hypertension) 
may experience an excessive blood pressure fall following the initial dose. A starting dose of 
2.5-5 mg is recommended in such patients and the initiation of treatment should take place 
under medical supervision. A lower starting dose is required in the presence of renal 
impairment (see Table 1 below).  
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Maintenance dose 
The usual effective maintenance dosage is 20 mg administered in a single daily dose. In 
general if the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks on a 
certain dose level, the dose can be further increased. The maximum dose used in long-term, 
controlled clinical trials was 80 mg/day.  
Diuretic-treated patients 
Symptomatic hypotension may occur following initiation of therapy with Lisinopril. This is 
more likely in patients who are being treated currently with diuretics. Caution is recommended 
therefore, since these patients may be volume and/or salt depleted. If possible, the diuretic 
should be discontinued 2 to 3 days before beginning therapy with Lisinopril. In hypertensive 
patients in whom the diuretic cannot be discontinued, therapy with Lisinopril should be 
initiated with a 5 mg dose. Renal function and serum potassium should be monitored. The 
subsequent dosage of Lisinopril should be adjusted according to blood pressure response. If 
required, diuretic therapy may be resumed (see section 4.4 and section 4.5).  
Dosage adjustment In renal impairment 
Dosage in patients with renal impairment should be based on creatinine clearance as outlined 
in Table 1 below.  
Table 1 Dosage adjustment in renal impairment.  
Creatinine Clearance (ml/min)  Starting Dose (mg/day) 
Less than 10 ml/min (including 
patients on dialysis) 
2.5 mg* 
10-30 ml/min  2.5-5 mg 
31-80 ml/min  5-10 mg 
* Dosage and/or frequency of administration should be adjusted depending on the blood 
pressure response.  
The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 
mg daily.  
Heart failure 
In patients with symptomatic heart failure, Lisinopril should be used as adjunctive therapy to 
diuretics and, where appropriate, digitalis or beta-blockers. Lisinopril may be initiated at a 
starting dose of 2.5 mg once a day, which should be administered under medical supervision 
to determine the initial effect on the blood pressure. The dose of Lisinopril should be 
increased:  
•   By increments of no greater than 10 mg  
•   At intervals of no less than 2 weeks  
•   To the highest dose tolerated by the patient up to a maximum of 35 mg once 
 daily   
Dose adjustment should be based on the clinical response of individual patients.  
Patients at high risk of symptomatic hypotension e.g. patients with salt depletion with or 
without hyponatraemia, patients with hypovolaemia or patients who have been receiving 
vigorous diuretic therapy should have these conditions corrected, if possible, prior to therapy 
with Lisinopril. Renal function and serum potassium should be monitored (see section 4.4).  
Acute myocardial infarction 
Patients should receive, as appropriate, the standard recommended treatments such as 
thrombolytics, aspirin, and beta-blockers. Intravenous or transdermal glyceryl trinitrate may 
be used together with Lisinopril.  UKPAR Lisinopril 2.5mg, 5mg, 10mg & 20mg Tablets  PL 20092/0008-11 
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Starting dose (first 3 days after infarction) 
Treatment with Lisinopril may be started within 24 hours of the onset of symptoms. Treatment 
should not be started if systolic blood pressure is lower than 100 mm Hg. The first dose of 
Lisinopril is 5 mg given orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and 
then 10 mg once daily. Patients with a low systolic blood pressure (120 mm Hg or less) when 
treatment is started or during the first 3 days after the infarction should be given a lower dose - 
2.5 mg orally (see section 4.4).  
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1).  
Maintenance dose 
The maintenance dose is 10 mg once daily. If hypotension occurs (systolic blood pressure less 
than or equal to 100 mm Hg) a daily maintenance dose of 5 mg may be given with temporary 
reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure less 
than 90 mm Hg for more than 1 hour) Lisinopril should be withdrawn.  
Treatment should continue for 6 weeks and then the patient should be re-evaluated. Patients 
who develop symptoms of heart failure should continue with Lisinopril (see section 4.2)  
Renal complications of diabetes mellitus 
In hypertensive patients with type 2 diabetes mellitus and incipient nephropathy, the dose is 
10 mg Lisinopril once daily which can be increased to 20 mg once daily, if necessary, to 
achieve a sitting diastolic blood pressure below 90 mm Hg.  
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1).  
Paediatric use 
Efficacy and safety of use in children has not been fully established. Therefore, use in children 
is not recommended.  
Use in the elderly 
In clinical studies, there was no age-related change in the efficacy or safety profile of the drug. 
When advanced age is associated with decrease in renal function, however, the guidelines set 
out in Table 1 should be used to determine the starting dose of Lisinopril. Thereafter, the 
dosage should be adjusted according to the blood pressure response.  
Use in kidney transplant patients 
There is no experience regarding the administration of Lisinopril in patients with recent 
kidney transplantation. Treatment with Lisinopril is therefore not recommended.  
 
4.3 CONTRAINDICATIONS 
•   Hypersensitivity to Lisinopril, to any of the excipients or any other angiotensin 
converting enzyme (ACE) inhibitor.  
•   History of angioedema associated with previous ACE inhibitor therapy  
•   Hereditary or idiopathic angioedema.  
•   Second or third trimesters of pregnancy (see section 4.6).  
 
4.4 SPECIAL  WARNINGS AND PRECAUTIONS FOR USE 
Symptomatic hypotension 
Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients. In 
hypertensive patients receiving Lisinopril, hypotension is more likely to occur if the patient 
has been volume-depleted e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea 
or vomiting, or has severe renin-dependent hypertension (see section 4.5 and section 4.8). In 
patients with heart failure, with or without associated renal insufficiency, symptomatic 
hypotension has been observed. This is most likely to occur in those patients with more severe 
degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia UKPAR Lisinopril 2.5mg, 5mg, 10mg & 20mg Tablets  PL 20092/0008-11 
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or functional renal impairment. In patients at increased risk of symptomatic hypotension, 
initiation of therapy and dose adjustment should be closely monitored. Similar considerations 
apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in 
blood pressure could result in a myocardial infarction or cerebrovascular accident.  
If hypotension occurs, the patient should be placed in the supine position and, if necessary, 
should receive an intravenous infusion of normal saline. A transient hypotensive response is 
not a contraindication to further doses, which can be given usually without difficulty once the 
blood pressure has increased after volume expansion.  
In some patients with heart failure who have normal or low blood pressure, additional 
lowering of systemic blood pressure may occur with Lisinopril. This effect is anticipated and 
is not usually a reason to discontinue treatment. If hypotension becomes symptomatic, a 
reduction of dose or discontinuation of Lisinopril may be necessary.  
Hypotension in acute myocardial infarction 
Treatment with Lisinopril must not be initiated in acute myocardial infarction patients who are 
at risk of further serious haemodynamic deterioration after treatment with a vasodilator. These 
are patients with systolic blood pressure of 100 mm Hg or lower or those in cardiogenic 
shock. During the first 3 days following the infarction, the dose should be reduced if the 
systolic blood pressure is 120 mm Hg or lower. Maintenance doses should be reduced to 5 mg 
or temporarily to 2.5 mg if systolic blood pressure is 100 mm Hg or lower. If hypotension 
persists (systolic blood pressure less than 90 mm Hg for more than 1 hour) then Lisinopril 
should be withdrawn.  
Aortic and mitral valve stenosis/hypertrophic cardiomyopathy  
As with other ACE inhibitors, Lisinopril should be given with caution to patients with mitral 
valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or 
hypertrophic cardiomyopathy.  
Renal function impairment 
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1 in section 4.2) 
and then as a function of the patient's response to treatment. Routine monitoring of potassium 
and creatinine is part of normal medical practice for these patients.  
In patients with heart failure, hypotension following the initiation of therapy with ACE 
inhibitors may lead to some further impairment in renal function. Acute renal failure, usually 
reversible, has been reported in this situation.  
In some patients with bilateral renal artery stenosis or with a stenosis of the artery to a solitary 
kidney, who have been treated with angiotensin converting enzyme inhibitors, increases in 
blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been 
seen. This is especially likely in patients with renal insufficiency. If renovascular hypertension 
is also present there is an increased risk of severe hypotension and renal insufficiency. In these 
patients, treatment should be started under close medical supervision with low doses and 
careful dose titration. Since treatment with diuretics may be a contributory factor to the above, 
they should be discontinued and renal function should be monitored during the first weeks of 
Lisinopril therapy.  
Some hypertensive patients with no apparent pre-existing renal vascular disease have 
developed increases in blood urea and serum creatinine, usually minor and transient, 
especially when Lisinopril has been given concomitantly with a diuretic. This is more likely to 
occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation 
of the diuretic and/or Lisinopril may be required.  
In acute myocardial infarction, treatment with Lisinopril should not be initiated in patients 
with evidence of renal dysfunction, defined as serum creatinine concentration exceeding 177 
micromol/l and/or proteinuria exceeding 500 mg/24 h. If renal dysfunction develops during 
treatment with Lisinopril (serum creatinine concentration exceeding 265 micromol/l or a 
doubling from the pre-treatment value) then the physician should consider withdrawal of 
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Hypersensitivity/Angioedema 
Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported 
rarely in patients treated with angiotensin converting enzyme inhibitors, including Lisinopril. 
This may occur at any time during therapy. In such cases, Lisinopril should be discontinued 
promptly and appropriate treatment and monitoring should be instituted to ensure complete 
resolution of symptoms prior to dismissing the patients. Even in those instances where 
swelling of only the tongue is involved, without respiratory distress, patients may require 
prolonged observation since treatment with antihistamines and corticosteroids may not be 
sufficient.  
Very rarely, fatalities have been reported due to angioedema associated with laryngeal oedema 
or tongue oedema. Patients with involvement of the tongue, glottis or larynx, are likely to 
experience airway obstruction, especially those with a history of airway surgery. In such cases 
emergency therapy should be administered promptly. This may include the administration of 
adrenaline and/or the maintenance of a patent airway. The patient should be under close 
medical supervision until complete and sustained resolution of symptoms has occurred.  
Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients 
than in non-black patients.  
Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased 
risk of angioedema while receiving an ACE inhibitor (see section 4.3).  
Anaphylactoid reactions in haemodialysis patients 
Anaphylactoid reactions have been reported in patients dialysed with high flux membranes 
(e.g. AN 69) and treated concomitantly with an ACE inhibitor. In these patients consideration 
should be given to using a different type of dialysis membrane or different class of 
antihypertensive agent.  
Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis 
Rarely, patients receiving ACE inhibitors during low-density lipoproteins (LDL) apheresis 
with dextran sulphate have experienced life-threatening anaphylactoid reactions. These 
reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each 
apheresis.  
Desensitisation 
Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) 
have sustained anaphylactoid reactions. In the same patients, these reactions have been 
avoided when ACE inhibitors were temporarily withheld but they have reappeared upon 
inadvertent re-administration of the medicinal product.  
Hepatic failure 
Very rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic 
jaundice and progresses to fulminant necrosis and (sometimes) death. The mechanism of this 
syndrome is not understood. Patients receiving Lisinopril who develop jaundice or marked 
elevations of hepatic enzymes should discontinue Lisinopril and receive appropriate medical 
follow-up.  
Neutropenia/Agranulocytosis 
Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients 
receiving ACE inhibitors. In patients with normal renal function and no other complicating 
factors, neutropenia occurs rarely. Neutropenia and agranulocytosis are reversible after 
discontinuation of the ACE inhibitor. Lisinopril should be used with extreme caution in 
patients with collagen vascular disease, immunosuppressant therapy, treatment with 
allopurinol or procainamide, or a combination of these complicating factors, especially if there 
is pre-existing impaired renal function. Some of these patients developed serious infections, 
which in a few instances did not respond to intensive antibiotic therapy. If Lisinopril is used in 
such patients, periodic monitoring of white blood cell counts is advised and patients should be 
instructed to report any sign of infection.  
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Race 
Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients 
than in non-black patients.  
As with other ACE inhibitors, Lisinopril may be less effective in lowering blood pressure in 
black patients than in non-blacks, possibly because of a higher prevalence of low-renin states 
in the black hypertensive population.  
Cough 
Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-
productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced 
cough should be considered as part of the differential diagnosis of cough.  
Surgery/Anaesthesia 
In patients undergoing major surgery or during anaesthesia with agents that produce 
hypotension, Lisinopril may block angiotensin II formation secondary to compensatory renin 
release. If hypotension occurs and is considered to be due to this mechanism, it can be 
corrected by volume expansion.  
Hyperkalaemia 
Elevations in serum potassium have been observed in some patients treated with ACE 
inhibitors, including Lisinopril. Patients at risk for the development of hyperkalaemia include 
those with renal insufficiency, diabetes mellitus, or those using concomitant potassium-
sparing diuretics, potassium supplements or potassium-containing salt substitutes, or those 
patients taking other drugs associated with increases in serum potassium (e.g. heparin). If 
concomitant use of the above-mentioned agents is deemed appropriate, regular monitoring of 
serum potassium is recommended (see section 4.5).  
Diabetic patients 
In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should 
be closely monitored during the first month of treatment with an ACE inhibitor (see 4.5 
Interaction with other medicinal products and other forms of interaction).  
Lithium 
The combination of lithium and Lisinopril is generally not recommended (see section 4.5).  
Pregnancy and lactation 
Lisinopril should not be used during the first trimester of pregnancy. Lisinopril is 
contraindicated in the second and third trimesters of pregnancy (see section 4.3). When 
pregnancy is detected, lisinopril treatment should discontinue as soon as possible (see section 
4.6).  
Use of lisinopril is not recommended during breast-feeding. 
 
4.5  INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF 
INTERACTION 
Diuretics 
When a diuretic is added to the therapy of a patient receiving Lisinopril the antihypertensive 
effect is usually additive.  
Patients already on diuretics and especially those in whom diuretic therapy was recently 
instituted, may occasionally experience an excessive reduction of blood pressure when 
Lisinopril is added. The possibility of symptomatic hypotension with Lisinopril can be 
minimised by discontinuing the diuretic prior to initiation of treatment with Lisinopril (see 
section 4.4 and section 4.2).  
Potassium supplements, potassium-sparing diuretics or potassium-containing salt 
substitutes  
Although in clinical trials, serum potassium usually remained within normal limits, 
hyperkalaemia did occur in some patients. Risk factors for the development of hyperkalaemia UKPAR Lisinopril 2.5mg, 5mg, 10mg & 20mg Tablets  PL 20092/0008-11 
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include renal insufficiency, diabetes mellitus, and concomitant use of potassium-sparing 
diuretics (e.g. spironolactone, triamterene or amiloride), potassium supplements or potassium-
containing salt substitutes. The use of potassium supplements, potassium-sparing diuretics or 
potassium-containing salt substitutes, particularly in patients with impaired renal function, 
may lead to a significant increase in serum potassium.  
If Lisinopril is given with a potassium-losing diuretic, diuretic-induced hypokalaemia may be 
ameliorated.  
Lithium 
Reversible increases in serum lithium concentrations and toxicity have been reported during 
concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide 
diuretics may increase the risk of lithium toxicity and enhance the already increased lithium 
toxicity with ACE inhibitors. Use of Lisinopril with lithium is not recommended, but if the 
combination proves necessary, careful monitoring of serum lithium levels should be 
performed (see section 4.4).  
Non steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid ≥ 3g/day  
Chronic administration of NSAIDs may reduce the antihypertensive effect of an ACE 
inhibitor. NSAIDs and ACE inhibitors exert an additive effect on the increase in serum 
potassium and may result in a deterioration of renal function. These effects are usually 
reversible. Rarely, acute renal failure may occur, especially in patients with compromised 
renal function such as the elderly or dehydrated.  
Other antihypertensive agents 
Concomitant use of these agents may increase the hypotensive effects of Lisinopril. 
Concomitant use with glyceryl trinitrate and other nitrates, or other vasodilators, may further 
reduce blood pressure.  
Tricyclic antidepressants/Antipsychotics /Anaesthetics 
Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and 
antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see 
section 4.4).  
Sympathomimetics 
Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.  
Antidiabetics 
Epidemiological studies have suggested that concomitant administration of ACE inhibitors 
and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased 
blood glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be 
more likely to occur during the first weeks of combined treatment and in patients with renal 
impairment.  
Acetylsalicylic acid, thrombolytics, beta-blockers, nitrates 
Lisinopril may be used concomitantly with acetylsalicylic acid (at cardiologic doses), 
thrombolytics, beta-blockers and/or nitrates. 
 
4.6 PREGNANCY  AND  LACTATION 
Pregnancy 
Lisinopril should not be used during the first trimester of pregnancy. When pregnancy is 
planned or confirmed the switch to an alternative treatment should be initiated as soon as 
possible. Controlled studies with ACE inhibitors have not been done in humans, but a limited 
number of cases with first trimester toxicity exposure have not appeared to manifest 
malformations consistent with human foetotoxicity as described below.  
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Prolonged ACE inhibitor exposure during the second and third trimesters is known to induce 
human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) 
and neonatal toxicity (renal failure, hypotension, hyperkalaemia (see also section 5.3).  
Should exposure to Lisinopril have occurred from the second trimester of pregnancy, an 
ultrasound check of renal function and the skull is recommended.  
Infants whose mothers have taken Lisinopril should be closely observed for hypotension, 
oliguria and hyperkalaemia. Lisinopril, which crosses the placenta, has been removed from the 
neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be 
removed by exchange transfusion.  
Lactation 
It is not known whether Lisinopril is excreted into human breast milk. Lisinopril is excreted 
into the milk of lactating rats. The use of Lisinopril is not recommended in women who are 
breast-feeding. 
 
4.7  EFFECTS ON ABILITY TO DRIVE AND USE MACHINES 
Lisinopril may have a minor or moderate effect on ability to drive and use machines. Patients 
who experience tiredness or dizziness should not drive or use machinery. 
 
4.8 UNDESIRABLE  EFFECTS 
The following undesirable effects have been observed and reported during treatment with 
Lisinopril and other ACE inhibitors with the following frequencies: Very common (≥10%), 
common (≥1%,<10%), uncommon (≥ 0.1, <1%), rare (≥ 0.01, <0.1%), very rare (<0.01%) 
including isolated reports.  
Blood and the lymphatic system disorders:  
rare:     decreases in haemoglobin, decreases in haematocrit.  
very rare:   bone marrow depression, anaemia, thrombocytopenia, leucopenia,  
    neutropenia, agranulocytosis (see section 4.4), haemolytic anaemia,  
  lymphadenopathy,  autoimmune  disease.   
Metabolism and nutrition disorders:  
very rare:   hypoglycaemia.  
 
Nervous system and psychiatric disorders:  
common:   dizziness, headache  
uncommon:   mood alterations, paraesthesia, vertigo, taste disturbance, sleep  
  disturbances.   
rare:     mental confusion.  
Cardiac and vascular disorders:  
common:   orthostatic effects (including hypotension)  
uncommon:   myocardial infarction or cerebrovascular accident, possibly secondary to 
excessive hypotension in high risk patients (see section 4.4), palpitations, 
tachycardia. Raynaud's phenomenon.  
Respiratory, thoracic and mediastinal disorders:  
common:   cough  
uncommon:   rhinitis  
very rare:   bronchospasm, sinusitis. Allergic alveolitis/eosinophilic pneumonia.  
Gastrointestinal disorders:  
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uncommon:   nausea, abdominal pain and indigestion  
rare:     dry mouth  
very rare:   pancreatitis, intestinal angioedema, hepatitis - either hepatocellular or  
    cholestatic, jaundice and hepatic failure (see section 4.4).  
Skin and subcutaneous tissue disorders:  
uncommon: rash,  pruritus   
rare:     hypersensitivity/angioneurotic oedema: angioneurotic oedema of the  
    face, extremities, lips, tongue, glottis, and/or larynx (see section 4.4),  
    urticaria, alopecia, psoriasis.  
very rare:   diaphoresis, pemphigus, toxic epidermal necrolysis, Stevens-Johnson  
  Syndrome,  erythema  multiforme.   
A symptom complex has been reported which may include one or more of the following: 
fever, vasculitis, myalgia, arthralgia/arthritis, a positive antinuclear antibodies (ANA), 
elevated red blood cell sedimentation rate (ESR), eosinophilia and leucocytosis, rash, 
photosensitivity or other dermatological manifestations may occur.  
Renal and urinary disorders:  
common: renal  dysfunction   
rare:     uraemia, acute renal failure  
very rare:   oliguria/anuria.  
Reproductive system and breast disorders:  
uncommon:   impotence  
rare:     gynaecomastia.  
General disorders and administration site conditions:  
uncommon:   fatigue, asthenia.  
Investigations:  
uncommon:   increases in blood urea, increases in serum creatinine, increases in  
    liver enzymes, hyperkalaemia.  
rare:     increases in serum bilirubin, hyponatraemia 
 
4.9 OVERDOSE 
Limited data are available for overdose in humans. Symptoms associated with overdosage of 
ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal 
failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.  
The recommended treatment of overdose is intravenous infusion of normal saline solution. If 
hypotension occurs, the patient should be placed in the shock position. If available, treatment 
with angiotensin II infusion and/or intravenous catecholamines may also be considered. If 
ingestion is recent, take measures aimed at eliminating Lisinopril (e.g. emesis, gastric lavage, 
administration of absorbents and sodium sulphate). Lisinopril may be removed from the 
general circulation by haemodialysis (see 4.4 special warning and precautions for use). 
Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum 
electrolytes and creatinine concentrations should be monitored frequently.  
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5 PHARMACOLOGICAL  PROPERTIES 
5.1 PHARMACODYNAMIC  PROPERTIES 
Pharmacotherapeutic group: Angiotensin converting enzyme inhibitors, ATC code: C09A 
A03.  
Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin converting enzyme 
(ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, 
angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. 
Inhibition of ACE results in decreased concentrations of angiotensin II which results in 
decreased vasopressor activity and reduced aldosterone secretion. The latter decrease may 
result in an increase in serum potassium concentration.  
Whilst the mechanism through which lisinopril lowers blood pressure is believed to be 
primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is 
antihypertensive even in patients with low renin hypertension. ACE is identical to kininase II, 
an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent 
vasodilatory peptide, play a role in the therapeutic effects of lisinopril remains to be 
elucidated.  
The effect of Lisinopril on mortality and morbidity in heart failure has been studied by 
comparing a high dose (32.5 mg or 35 mg once daily) with a low dose (2.5 mg or 5 mg once 
daily). In a study of 3164 patients, with a median follow up period of 46 months for surviving 
patients, high dose Lisinopril produced a 12% risk reduction in the combined endpoint of all-
cause mortality and all-cause hospitalisation (p = 0.002) and an 8% risk reduction in all-cause 
mortality and cardiovascular hospitalisation (p = 0.036) compared with low dose. Risk 
reductions for all-cause mortality (8%; p = 0.128) and cardiovascular mortality (10%; p = 
0.073) were observed. In a post-hoc analysis, the number of hospitalisations for heart failure 
was reduced by 24% (p=0.002) in patients treated with high-dose Lisinopril compared with 
low dose. Symptomatic benefits were similar in patients treated with high and low doses of 
Lisinopril.  
The results of the study showed that the overall adverse event profiles for patients treated with 
high or low dose Lisinopril were similar in both nature and number. Predictable events 
resulting from ACE inhibition, such as hypotension or altered renal function, were 
manageable and rarely led to treatment withdrawal. Cough was less frequent in patients 
treated with high dose Lisinopril compared with low dose.  
In the GISSI-3 trial, which used a 2x2 factorial design to compare the effects of Lisinopril and 
glyceryl trinitrate given alone or in combination for 6 weeks versus control in 19,394, patients 
who were administered the treatment within 24 hours of an acute myocardial infarction, 
Lisinopril produced a statistically significant risk reduction in mortality of 11% versus control 
(2p=0.03). The risk reduction with glyceryl trinitrate was not significant but the combination 
of Lisinopril and glyceryl trinitrate produced a significant risk reduction in mortality of 17% 
versus control (2p=0.02). In the sub-groups of elderly (age > 70 years) and females, pre-
defined as patients at high risk of mortality, significant benefit was observed for a combined 
endpoint of mortality and cardiac function. The combined endpoint for all patients, as well as 
the high-risk sub-groups, at 6 months also showed significant benefit for those treated with 
Lisinopril or Lisinopril plus glyceryl trinitrate for 6 weeks, indicating a prevention effect for 
Lisinopril. As would be expected from any vasodilator treatment, increased incidences of 
hypotension and renal dysfunction were associated with Lisinopril treatment but these were 
not associated with a proportional increase in mortality.  
In a double-blind, randomised, multicentre trial which compared Lisinopril with a calcium 
channel blocker in 335 hypertensive Type 2 diabetes mellitus subjects with incipient 
nephropathy characterised by microalbuminuria, Lisinopril 10 mg to 20 mg administered once 
daily for 12 months, reduced systolic/diastolic blood pressure by 13/10 mmHg and urinary 
albumin excretion rate by 40%. When compared with the calcium channel blocker, which 
produced a similar reduction in blood pressure, those treated with Lisinopril showed a 
significantly greater reduction in urinary albumin excretion rate, providing evidence that the 
ACE inhibitory action of Lisinopril reduced microalbuminuria by a direct mechanism on renal 
tissues in addition to its blood pressure lowering effect.  
Lisinopril treatment does not affect glycaemic control as shown by a lack of significant effect 
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5.2 PHARMACOKINETIC PROPERTIES 
Lisinopril is an orally active non-sulphydryl-containing ACE inhibitor.  
Absorption 
Following oral administration of lisinopril, peak serum concentrations occur within about 7 
hours, although there was a trend to a small delay in time taken to reach peak serum 
concentrations in acute myocardial infarction patients. Based on urinary recovery, the mean 
extent of absorption of lisinopril is approximately 25% with interpatient variability of 6-60% 
over the dose range studied (5-80 mg). The absolute bioavailability is reduced approximately 
16% in patients with heart failure. Lisinopril absorption is not affected by the presence of 
food.  
Distribution 
Lisinopril does not appear to be bound to serum proteins other than to circulating angiotensin 
converting enzyme (ACE). Studies in rats indicate that lisinopril crosses the blood-brain 
barrier poorly.  
Elimination 
Lisinopril does not undergo metabolism and is excreted entirely unchanged in the urine. On 
multiple dosing lisinopril has an effective half-life of accumulation of 12.6 hours. The 
clearance of lisinopril in healthy subjects is approximately 50 ml/min. Declining serum 
concentrations exhibit a prolonged terminal phase, which does not contribute to drug 
accumulation. This terminal phase probably represents saturable binding to ACE and is not 
proportional to dose.  
Hepatic impairment 
Impairment of hepatic function in cirrhotic patients resulted in a decrease in lisinopril 
absorption (about 30% as determined by urinary recovery) but an increase in exposure 
(approximately 50%) compared to healthy subjects due to decreased clearance.  
Renal impairment 
Impaired renal function decreases elimination of lisinopril, which is excreted via the kidneys, 
but this decrease becomes clinically important only when the glomerular filtration rate is 
below 30 ml/min. In mild to moderate renal impairment (creatinine clearance 30-80 ml/min) 
mean AUC was increased by 13% only, while a 4.5- fold increase in mean AUC was observed 
in severe renal impairment (creatinine clearance 5-30 ml/min).  
Lisinopril can be removed by dialysis. During 4 hours of haemodialysis, plasma lisinopril 
concentrations decreased on average by 60%, with a dialysis clearance between 40 and 55 
ml/min.  
Heart failure 
Patients with heart failure have a greater exposure of lisinopril when compared to healthy 
subjects (an increase in AUC on average of 125%), but based on the urinary recovery of 
lisinopril, there is reduced absorption of approximately 16% compared to healthy subjects.  
Elderly 
Older patients have higher blood levels and higher values for the area under the plasma 
concentration time curve (increased approximately 60%) compared with younger subjects. 
 
5.3 PRECLINICAL  SAFETY  DATA 
Preclinical data reveal no special hazard for humans based on conventional studies of general 
pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Angiotensin 
converting enzyme inhibitors, as a class, have been shown to induce adverse effects on the late 
foetal development, resulting in foetal death and congenital effects, in particular affecting the 
skull. Foetotoxicity, intrauterine growth retardation and patent ductus arteriosus have also 
been reported. These developmental anomalies are thought to be partly due to a direct action 
of ACE inhibitors on the foetal renin-angiotensin system and partly due to ischaemia resulting 
from maternal hypotension and decreases in foetal-placental blood flow and oxygen/nutrients 
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6 PHARMACEUTICAL  PARTICULARS 
6.1  LIST OF EXCIPIENTS 
Mannitol  
Calcium Hydrogen Phosphate 
Maize Starch  
Pregelatinised Starch 
Colloidal Anhydrous Silica  
Magnesium Stearate 
 
6.2 INCOMPATIBILITIES 
Not applicable. 
 
6.3 SHELF  LIFE 
3 years. 
 
6.4 SPECIAL  PRECAUTIONS FOR STORAGE 
Store below 25°C. Store in the original package. 
 
6.5  NATURE AND CONTENTS OF CONTAINER 
PVC / PVDC Aluminium blister packs in a carton in pack sizes of 28 tablets. 
 
6.6 SPECIAL  PRECAUTIONS FOR DISPOSAL 
No special requirements. 
Any unused product or waste material should be disposed of in accordance with local 
requirements 
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Lupin (Europe) Limited 
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SUMMARY OF PRODUCT CHARACTERISTICS 
The UK Summary of Product Characteristics (SPC) for Lisinopril 5mg Tablets is as 
follows: 
 
1  NAME OF THE MEDICINAL PRODUCT 
Lisinopril 5 mg tablets. 
 
2  QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each uncoated tablet contains Lisinopril Dihydrate equivalent to 5 mg of anhydrous 
Lisinopril.  
For a full list of excipients, see section 6.1. 
 
3 PHARMACEUTICAL  FORM 
Tablet 
Pink, round tablets marked ‘5’on one side and scoreline on other side. 
The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal 
doses. 
 
4 CLINICAL  PARTICULARS 
4.1 THERAPEUTIC  INDICATIONS 
Hypertension 
Treatment of hypertension.  
Heart failure 
Treatment of symptomatic heart failure.  
Acute myocardial infarction 
Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an 
acute myocardial infarction.  
Renal complications of diabetes mellitus 
Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient 
nephropathy (see section 5.1). 
 
4.2  POSOLOGY AND METHOD OF ADMINISTRATION 
Lisinopril should be administered orally in a single daily dose. As with all other medication 
taken once daily, Lisinopril should be taken at approximately the same time each day. The 
absorption of Lisinopril tablets is not affected by food.  
The dose should be individualised according to patient profile and blood pressure response 
(see section 4.4).  
Hypertension 
Lisinopril may be used as monotherapy or in combination with other classes of 
antihypertensive therapy.  
Starting dose 
In patients with hypertension the usual recommended starting dose is 10 mg. Patients with a 
strongly activated renin-angiotensin-aldosterone system (in particular, renovascular 
hypertension, salt and /or volume depletion, cardiac decompensation, or severe hypertension) 
may experience an excessive blood pressure fall following the initial dose. A starting dose of 
2.5-5 mg is recommended in such patients and the initiation of treatment should take place 
under medical supervision. A lower starting dose is required in the presence of renal 
impairment (see Table 1 below).  
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Maintenance dose 
The usual effective maintenance dosage is 20 mg administered in a single daily dose. In 
general if the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks on a 
certain dose level, the dose can be further increased. The maximum dose used in long-term, 
controlled clinical trials was 80 mg/day.  
Diuretic-treated patients 
Symptomatic hypotension may occur following initiation of therapy with Lisinopril. This is 
more likely in patients who are being treated currently with diuretics. Caution is recommended 
therefore, since these patients may be volume and/or salt depleted. If possible, the diuretic 
should be discontinued 2 to 3 days before beginning therapy with Lisinopril. In hypertensive 
patients in whom the diuretic cannot be discontinued, therapy with Lisinopril should be 
initiated with a 5 mg dose. Renal function and serum potassium should be monitored. The 
subsequent dosage of Lisinopril should be adjusted according to blood pressure response. If 
required, diuretic therapy may be resumed (see section 4.4 and section 4.5).  
Dosage adjustment In renal impairment 
Dosage in patients with renal impairment should be based on creatinine clearance as outlined 
in Table 1 below.  
Table 1 Dosage adjustment in renal impairment.  
Creatinine Clearance (ml/min)  Starting Dose (mg/day) 
Less than 10 ml/min (including 
patients on dialysis) 
2.5 mg* 
10-30 ml/min  2.5-5 mg 
31-80 ml/min  5-10 mg 
* Dosage and/or frequency of administration should be adjusted depending on the blood 
pressure response.  
The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 
mg daily.  
Heart failure 
In patients with symptomatic heart failure, Lisinopril should be used as adjunctive therapy to 
diuretics and, where appropriate, digitalis or beta-blockers. Lisinopril may be initiated at a 
starting dose of 2.5 mg once a day, which should be administered under medical supervision 
to determine the initial effect on the blood pressure. The dose of Lisinopril should be 
increased:  
•   By increments of no greater than 10 mg  
•   At intervals of no less than 2 weeks  
•   To the highest dose tolerated by the patient up to a maximum of 35 mg once 
 daily   
Dose adjustment should be based on the clinical response of individual patients.  
Patients at high risk of symptomatic hypotension e.g. patients with salt depletion with or 
without hyponatraemia, patients with hypovolaemia or patients who have been receiving 
vigorous diuretic therapy should have these conditions corrected, if possible, prior to therapy 
with Lisinopril. Renal function and serum potassium should be monitored (see section 4.4).  
Acute myocardial infarction 
Patients should receive, as appropriate, the standard recommended treatments such as 
thrombolytics, aspirin, and beta-blockers. Intravenous or transdermal glyceryl trinitrate may 
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Starting dose (first 3 days after infarction) 
Treatment with Lisinopril may be started within 24 hours of the onset of symptoms. Treatment 
should not be started if systolic blood pressure is lower than 100 mm Hg. The first dose of 
Lisinopril is 5 mg given orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and 
then 10 mg once daily. Patients with a low systolic blood pressure (120 mm Hg or less) when 
treatment is started or during the first 3 days after the infarction should be given a lower dose - 
2.5 mg orally (see section 4.4).  
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1).  
Maintenance dose 
The maintenance dose is 10 mg once daily. If hypotension occurs (systolic blood pressure less 
than or equal to 100 mm Hg) a daily maintenance dose of 5 mg may be given with temporary 
reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure less 
than 90 mm Hg for more than 1 hour) Lisinopril should be withdrawn.  
Treatment should continue for 6 weeks and then the patient should be re-evaluated. Patients 
who develop symptoms of heart failure should continue with Lisinopril (see section 4.2)  
Renal complications of diabetes mellitus 
In hypertensive patients with type 2 diabetes mellitus and incipient nephropathy, the dose is 
10 mg Lisinopril once daily which can be increased to 20 mg once daily, if necessary, to 
achieve a sitting diastolic blood pressure below 90 mm Hg.  
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1).  
Paediatric use 
Efficacy and safety of use in children has not been fully established. Therefore, use in children 
is not recommended.  
Use in the elderly 
In clinical studies, there was no age-related change in the efficacy or safety profile of the drug. 
When advanced age is associated with decrease in renal function, however, the guidelines set 
out in Table 1 should be used to determine the starting dose of Lisinopril. Thereafter, the 
dosage should be adjusted according to the blood pressure response.  
Use in kidney transplant patients 
There is no experience regarding the administration of Lisinopril in patients with recent 
kidney transplantation. Treatment with Lisinopril is therefore not recommended.  
 
4.3 CONTRAINDICATIONS 
•   Hypersensitivity to Lisinopril, to any of the excipients or any other angiotensin 
converting enzyme (ACE) inhibitor.  
•   History of angioedema associated with previous ACE inhibitor therapy  
•   Hereditary or idiopathic angioedema.  
•   Second or third trimesters of pregnancy (see section 4.6).  
 
4.4 SPECIAL  WARNINGS AND PRECAUTIONS FOR USE 
Symptomatic hypotension 
Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients. In 
hypertensive patients receiving Lisinopril, hypotension is more likely to occur if the patient 
has been volume-depleted e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea 
or vomiting, or has severe renin-dependent hypertension (see section 4.5 and section 4.8). In 
patients with heart failure, with or without associated renal insufficiency, symptomatic 
hypotension has been observed. This is most likely to occur in those patients with more severe 
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or functional renal impairment. In patients at increased risk of symptomatic hypotension, 
initiation of therapy and dose adjustment should be closely monitored. Similar considerations 
apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in 
blood pressure could result in a myocardial infarction or cerebrovascular accident.  
If hypotension occurs, the patient should be placed in the supine position and, if necessary, 
should receive an intravenous infusion of normal saline. A transient hypotensive response is 
not a contraindication to further doses, which can be given usually without difficulty once the 
blood pressure has increased after volume expansion.  
In some patients with heart failure who have normal or low blood pressure, additional 
lowering of systemic blood pressure may occur with Lisinopril. This effect is anticipated and 
is not usually a reason to discontinue treatment. If hypotension becomes symptomatic, a 
reduction of dose or discontinuation of Lisinopril may be necessary.  
Hypotension in acute myocardial infarction 
Treatment with Lisinopril must not be initiated in acute myocardial infarction patients who are 
at risk of further serious haemodynamic deterioration after treatment with a vasodilator. These 
are patients with systolic blood pressure of 100 mm Hg or lower or those in cardiogenic 
shock. During the first 3 days following the infarction, the dose should be reduced if the 
systolic blood pressure is 120 mm Hg or lower. Maintenance doses should be reduced to 5 mg 
or temporarily to 2.5 mg if systolic blood pressure is 100 mm Hg or lower. If hypotension 
persists (systolic blood pressure less than 90 mm Hg for more than 1 hour) then Lisinopril 
should be withdrawn.  
Aortic and mitral valve stenosis/hypertrophic cardiomyopathy  
As with other ACE inhibitors, Lisinopril should be given with caution to patients with mitral 
valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or 
hypertrophic cardiomyopathy.  
Renal function impairment 
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1 in section 4.2) 
and then as a function of the patient's response to treatment. Routine monitoring of potassium 
and creatinine is part of normal medical practice for these patients.  
In patients with heart failure, hypotension following the initiation of therapy with ACE 
inhibitors may lead to some further impairment in renal function. Acute renal failure, usually 
reversible, has been reported in this situation.  
In some patients with bilateral renal artery stenosis or with a stenosis of the artery to a solitary 
kidney, who have been treated with angiotensin converting enzyme inhibitors, increases in 
blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been 
seen. This is especially likely in patients with renal insufficiency. If renovascular hypertension 
is also present there is an increased risk of severe hypotension and renal insufficiency. In these 
patients, treatment should be started under close medical supervision with low doses and 
careful dose titration. Since treatment with diuretics may be a contributory factor to the above, 
they should be discontinued and renal function should be monitored during the first weeks of 
Lisinopril therapy.  
Some hypertensive patients with no apparent pre-existing renal vascular disease have 
developed increases in blood urea and serum creatinine, usually minor and transient, 
especially when Lisinopril has been given concomitantly with a diuretic. This is more likely to 
occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation 
of the diuretic and/or Lisinopril may be required.  
In acute myocardial infarction, treatment with Lisinopril should not be initiated in patients 
with evidence of renal dysfunction, defined as serum creatinine concentration exceeding 177 
micromol/l and/or proteinuria exceeding 500 mg/24 h. If renal dysfunction develops during 
treatment with Lisinopril (serum creatinine concentration exceeding 265 micromol/l or a 
doubling from the pre-treatment value) then the physician should consider withdrawal of 
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Hypersensitivity/Angioedema 
Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported 
rarely in patients treated with angiotensin converting enzyme inhibitors, including Lisinopril. 
This may occur at any time during therapy. In such cases, Lisinopril should be discontinued 
promptly and appropriate treatment and monitoring should be instituted to ensure complete 
resolution of symptoms prior to dismissing the patients. Even in those instances where 
swelling of only the tongue is involved, without respiratory distress, patients may require 
prolonged observation since treatment with antihistamines and corticosteroids may not be 
sufficient.  
Very rarely, fatalities have been reported due to angioedema associated with laryngeal oedema 
or tongue oedema. Patients with involvement of the tongue, glottis or larynx, are likely to 
experience airway obstruction, especially those with a history of airway surgery. In such cases 
emergency therapy should be administered promptly. This may include the administration of 
adrenaline and/or the maintenance of a patent airway. The patient should be under close 
medical supervision until complete and sustained resolution of symptoms has occurred.  
Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients 
than in non-black patients.  
Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased 
risk of angioedema while receiving an ACE inhibitor (see section 4.3).  
Anaphylactoid reactions in haemodialysis patients 
Anaphylactoid reactions have been reported in patients dialysed with high flux membranes 
(e.g. AN 69) and treated concomitantly with an ACE inhibitor. In these patients consideration 
should be given to using a different type of dialysis membrane or different class of 
antihypertensive agent.  
Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis 
Rarely, patients receiving ACE inhibitors during low-density lipoproteins (LDL) apheresis 
with dextran sulphate have experienced life-threatening anaphylactoid reactions. These 
reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each 
apheresis.  
Desensitisation 
Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) 
have sustained anaphylactoid reactions. In the same patients, these reactions have been 
avoided when ACE inhibitors were temporarily withheld but they have reappeared upon 
inadvertent re-administration of the medicinal product.  
Hepatic failure 
Very rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic 
jaundice and progresses to fulminant necrosis and (sometimes) death. The mechanism of this 
syndrome is not understood. Patients receiving Lisinopril who develop jaundice or marked 
elevations of hepatic enzymes should discontinue Lisinopril and receive appropriate medical 
follow-up.  
Neutropenia/Agranulocytosis 
Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients 
receiving ACE inhibitors. In patients with normal renal function and no other complicating 
factors, neutropenia occurs rarely. Neutropenia and agranulocytosis are reversible after 
discontinuation of the ACE inhibitor. Lisinopril should be used with extreme caution in 
patients with collagen vascular disease, immunosuppressant therapy, treatment with 
allopurinol or procainamide, or a combination of these complicating factors, especially if there 
is pre-existing impaired renal function. Some of these patients developed serious infections, 
which in a few instances did not respond to intensive antibiotic therapy. If Lisinopril is used in 
such patients, periodic monitoring of white blood cell counts is advised and patients should be 
instructed to report any sign of infection.  
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Race 
Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients 
than in non-black patients.  
As with other ACE inhibitors, Lisinopril may be less effective in lowering blood pressure in 
black patients than in non-blacks, possibly because of a higher prevalence of low-renin states 
in the black hypertensive population.  
Cough 
Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-
productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced 
cough should be considered as part of the differential diagnosis of cough.  
Surgery/Anaesthesia 
In patients undergoing major surgery or during anaesthesia with agents that produce 
hypotension, Lisinopril may block angiotensin II formation secondary to compensatory renin 
release. If hypotension occurs and is considered to be due to this mechanism, it can be 
corrected by volume expansion.  
Hyperkalaemia 
Elevations in serum potassium have been observed in some patients treated with ACE 
inhibitors, including Lisinopril. Patients at risk for the development of hyperkalaemia include 
those with renal insufficiency, diabetes mellitus, or those using concomitant potassium-
sparing diuretics, potassium supplements or potassium-containing salt substitutes, or those 
patients taking other drugs associated with increases in serum potassium (e.g. heparin). If 
concomitant use of the above-mentioned agents is deemed appropriate, regular monitoring of 
serum potassium is recommended (see section 4.5).  
Diabetic patients 
In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should 
be closely monitored during the first month of treatment with an ACE inhibitor (see 4.5 
Interaction with other medicinal products and other forms of interaction).  
Lithium 
The combination of lithium and Lisinopril is generally not recommended (see section 4.5).  
Pregnancy and lactation 
Lisinopril should not be used during the first trimester of pregnancy. Lisinopril is 
contraindicated in the second and third trimesters of pregnancy (see section 4.3). When 
pregnancy is detected, lisinopril treatment should discontinue as soon as possible (see section 
4.6).  
Use of lisinopril is not recommended during breast-feeding. 
 
4.5  INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF 
INTERACTION 
Diuretics 
When a diuretic is added to the therapy of a patient receiving Lisinopril the antihypertensive 
effect is usually additive.  
Patients already on diuretics and especially those in whom diuretic therapy was recently 
instituted, may occasionally experience an excessive reduction of blood pressure when 
Lisinopril is added. The possibility of symptomatic hypotension with Lisinopril can be 
minimised by discontinuing the diuretic prior to initiation of treatment with Lisinopril (see 
section 4.4 and section 4.2).  
Potassium supplements, potassium-sparing diuretics or potassium-containing salt 
substitutes  
Although in clinical trials, serum potassium usually remained within normal limits, 
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include renal insufficiency, diabetes mellitus, and concomitant use of potassium-sparing 
diuretics (e.g. spironolactone, triamterene or amiloride), potassium supplements or potassium-
containing salt substitutes. The use of potassium supplements, potassium-sparing diuretics or 
potassium-containing salt substitutes, particularly in patients with impaired renal function, 
may lead to a significant increase in serum potassium.  
If Lisinopril is given with a potassium-losing diuretic, diuretic-induced hypokalaemia may be 
ameliorated.  
Lithium 
Reversible increases in serum lithium concentrations and toxicity have been reported during 
concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide 
diuretics may increase the risk of lithium toxicity and enhance the already increased lithium 
toxicity with ACE inhibitors. Use of Lisinopril with lithium is not recommended, but if the 
combination proves necessary, careful monitoring of serum lithium levels should be 
performed (see section 4.4).  
Non steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid ≥ 3g/day  
Chronic administration of NSAIDs may reduce the antihypertensive effect of an ACE 
inhibitor. NSAIDs and ACE inhibitors exert an additive effect on the increase in serum 
potassium and may result in a deterioration of renal function. These effects are usually 
reversible. Rarely, acute renal failure may occur, especially in patients with compromised 
renal function such as the elderly or dehydrated.  
Other antihypertensive agents 
Concomitant use of these agents may increase the hypotensive effects of Lisinopril. 
Concomitant use with glyceryl trinitrate and other nitrates, or other vasodilators, may further 
reduce blood pressure.  
Tricyclic antidepressants/Antipsychotics /Anaesthetics 
Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and 
antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see 
section 4.4).  
Sympathomimetics 
Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.  
Antidiabetics 
Epidemiological studies have suggested that concomitant administration of ACE inhibitors 
and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased 
blood glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be 
more likely to occur during the first weeks of combined treatment and in patients with renal 
impairment.  
Acetylsalicylic acid, thrombolytics, beta-blockers, nitrates 
Lisinopril may be used concomitantly with acetylsalicylic acid (at cardiologic doses), 
thrombolytics, beta-blockers and/or nitrates. 
 
4.6 PREGNANCY  AND  LACTATION 
Pregnancy 
Lisinopril should not be used during the first trimester of pregnancy. When pregnancy is 
planned or confirmed the switch to an alternative treatment should be initiated as soon as 
possible. Controlled studies with ACE inhibitors have not been done in humans, but a limited 
number of cases with first trimester toxicity exposure have not appeared to manifest 
malformations consistent with human foetotoxicity as described below.  
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Prolonged ACE inhibitor exposure during the second and third trimesters is known to induce 
human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) 
and neonatal toxicity (renal failure, hypotension, hyperkalaemia (see also section 5.3).  
Should exposure to Lisinopril have occurred from the second trimester of pregnancy, an 
ultrasound check of renal function and the skull is recommended.  
Infants whose mothers have taken Lisinopril should be closely observed for hypotension, 
oliguria and hyperkalaemia. Lisinopril, which crosses the placenta, has been removed from the 
neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be 
removed by exchange transfusion.  
Lactation 
It is not known whether Lisinopril is excreted into human breast milk. Lisinopril is excreted 
into the milk of lactating rats. The use of Lisinopril is not recommended in women who are 
breast-feeding.  
 
4.7  EFFECTS ON ABILITY TO DRIVE AND USE MACHINES 
Lisinopril may have a minor or moderate effect on ability to drive and use machines. Patients 
who experience tiredness or dizziness should not drive or use machinery.  
 
4.8 UNDESIRABLE  EFFECTS 
The following undesirable effects have been observed and reported during treatment with 
Lisinopril and other ACE inhibitors with the following frequencies: Very common (≥10%), 
common (≥1%,<10%), uncommon (≥ 0.1, <1%), rare (≥ 0.01, <0.1%), very rare (<0.01%) 
including isolated reports.  
Blood and the lymphatic system disorders:  
rare:     decreases in haemoglobin, decreases in haematocrit.  
very rare:   bone marrow depression, anaemia, thrombocytopenia, leucopenia,  
    neutropenia, agranulocytosis (see section 4.4), haemolytic anaemia,  
  lymphadenopathy,  autoimmune  disease.   
Metabolism and nutrition disorders:  
very rare:   hypoglycaemia.  
Nervous system and psychiatric disorders:  
common:   dizziness, headache  
uncommon:   mood alterations, paraesthesia, vertigo, taste disturbance, sleep  
  disturbances.   
rare:     mental confusion.  
Cardiac and vascular disorders:  
common:   orthostatic effects (including hypotension)  
uncommon:   myocardial infarction or cerebrovascular accident, possibly secondary to 
excessive hypotension in high risk patients (see section 4.4), palpitations, 
tachycardia. Raynaud's phenomenon.  
Respiratory, thoracic and mediastinal disorders:  
common:   cough  
uncommon: rhinitis   
very rare:   bronchospasm, sinusitis. Allergic alveolitis/eosinophilic pneumonia.  
Gastrointestinal disorders:  
common:   diarrhoea, vomiting  
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rare:     dry mouth  
very rare:   pancreatitis, intestinal angioedema, hepatitis - either hepatocellular or  
    cholestatic, jaundice and hepatic failure (see section 4.4).  
Skin and subcutaneous tissue disorders:  
uncommon:   rash, pruritus  
rare:     hypersensitivity/angioneurotic oedema: angioneurotic oedema of the  
    face, extremities, lips, tongue, glottis, and/or larynx (see section 4.4),  
    urticaria, alopecia, psoriasis.  
very rare:   diaphoresis, pemphigus, toxic epidermal necrolysis, Stevens-Johnson  
  Syndrome,  erythema  multiforme.   
A symptom complex has been reported which may include one or more of the following: 
fever, vasculitis, myalgia, arthralgia/arthritis, a positive antinuclear antibodies (ANA), 
elevated red blood cell sedimentation rate (ESR), eosinophilia and leucocytosis, rash, 
photosensitivity or other dermatological manifestations may occur.  
Renal and urinary disorders:  
common:   renal dysfunction  
rare:     uraemia, acute renal failure  
very rare:   oliguria/anuria.  
Reproductive system and breast disorders:  
uncommon:   impotence  
rare:     gynaecomastia.  
General disorders and administration site conditions:  
uncommon:   fatigue, asthenia.  
Investigations:  
uncommon:   increases in blood urea, increases in serum creatinine, increases in  
    liver enzymes, hyperkalaemia.  
rare:     increases in serum bilirubin, hyponatraemia.  
 
4.9 OVERDOSE 
Limited data are available for overdose in humans. Symptoms associated with overdosage of 
ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal 
failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.  
The recommended treatment of overdose is intravenous infusion of normal saline solution. If 
hypotension occurs, the patient should be placed in the shock position. If available, treatment 
with angiotensin II infusion and/or intravenous catecholamines may also be considered. If 
ingestion is recent, take measures aimed at eliminating Lisinopril (e.g. emesis, gastric lavage, 
administration of absorbents and sodium sulphate). Lisinopril may be removed from the 
general circulation by haemodialysis (see 4.4 special warning and precautions for use). 
Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum 
electrolytes and creatinine concentrations should be monitored frequently.  
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5 PHARMACOLOGICAL  PROPERTIES 
5.1 PHARMACODYNAMIC  PROPERTIES 
Pharmacotherapeutic group: Angiotensin converting enzyme inhibitors, ATC code: C09A 
A03.  
Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin converting enzyme 
(ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, 
angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. 
Inhibition of ACE results in decreased concentrations of angiotensin II which results in 
decreased vasopressor activity and reduced aldosterone secretion. The latter decrease may 
result in an increase in serum potassium concentration.  
Whilst the mechanism through which lisinopril lowers blood pressure is believed to be 
primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is 
antihypertensive even in patients with low renin hypertension. ACE is identical to kininase II, 
an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent 
vasodilatory peptide, play a role in the therapeutic effects of lisinopril remains to be 
elucidated.  
The effect of Lisinopril on mortality and morbidity in heart failure has been studied by 
comparing a high dose (32.5 mg or 35 mg once daily) with a low dose (2.5 mg or 5 mg once 
daily). In a study of 3164 patients, with a median follow up period of 46 months for surviving 
patients, high dose Lisinopril produced a 12% risk reduction in the combined endpoint of all-
cause mortality and all-cause hospitalisation (p = 0.002) and an 8% risk reduction in all-cause 
mortality and cardiovascular hospitalisation (p = 0.036) compared with low dose. Risk 
reductions for all-cause mortality (8%; p = 0.128) and cardiovascular mortality (10%; p = 
0.073) were observed. In a post-hoc analysis, the number of hospitalisations for heart failure 
was reduced by 24% (p=0.002) in patients treated with high-dose Lisinopril compared with 
low dose. Symptomatic benefits were similar in patients treated with high and low doses of 
Lisinopril.  
The results of the study showed that the overall adverse event profiles for patients treated with 
high or low dose Lisinopril were similar in both nature and number. Predictable events 
resulting from ACE inhibition, such as hypotension or altered renal function, were 
manageable and rarely led to treatment withdrawal. Cough was less frequent in patients 
treated with high dose Lisinopril compared with low dose.  
In the GISSI-3 trial, which used a 2x2 factorial design to compare the effects of Lisinopril and 
glyceryl trinitrate given alone or in combination for 6 weeks versus control in 19,394, patients 
who were administered the treatment within 24 hours of an acute myocardial infarction, 
Lisinopril produced a statistically significant risk reduction in mortality of 11% versus control 
(2p=0.03). The risk reduction with glyceryl trinitrate was not significant but the combination 
of Lisinopril and glyceryl trinitrate produced a significant risk reduction in mortality of 17% 
versus control (2p=0.02). In the sub-groups of elderly (age > 70 years) and females, pre-
defined as patients at high risk of mortality, significant benefit was observed for a combined 
endpoint of mortality and cardiac function. The combined endpoint for all patients, as well as 
the high-risk sub-groups, at 6 months also showed significant benefit for those treated with 
Lisinopril or Lisinopril plus glyceryl trinitrate for 6 weeks, indicating a prevention effect for 
Lisinopril. As would be expected from any vasodilator treatment, increased incidences of 
hypotension and renal dysfunction were associated with Lisinopril treatment but these were 
not associated with a proportional increase in mortality.  
In a double-blind, randomised, multicentre trial which compared Lisinopril with a calcium 
channel blocker in 335 hypertensive Type 2 diabetes mellitus subjects with incipient 
nephropathy characterised by microalbuminuria, Lisinopril 10 mg to 20 mg administered once 
daily for 12 months, reduced systolic/diastolic blood pressure by 13/10 mmHg and urinary 
albumin excretion rate by 40%. When compared with the calcium channel blocker, which 
produced a similar reduction in blood pressure, those treated with Lisinopril showed a 
significantly greater reduction in urinary albumin excretion rate, providing evidence that the 
ACE inhibitory action of Lisinopril reduced microalbuminuria by a direct mechanism on renal 
tissues in addition to its blood pressure lowering effect.  
Lisinopril treatment does not affect glycaemic control as shown by a lack of significant effect 
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5.2 PHARMACOKINETIC PROPERTIES 
Lisinopril is an orally active non-sulphydryl-containing ACE inhibitor.  
Absorption 
Following oral administration of lisinopril, peak serum concentrations occur within about 7 
hours, although there was a trend to a small delay in time taken to reach peak serum 
concentrations in acute myocardial infarction patients. Based on urinary recovery, the mean 
extent of absorption of lisinopril is approximately 25% with interpatient variability of 6-60% 
over the dose range studied (5-80 mg). The absolute bioavailability is reduced approximately 
16% in patients with heart failure. Lisinopril absorption is not affected by the presence of 
food.  
Distribution 
Lisinopril does not appear to be bound to serum proteins other than to circulating angiotensin 
converting enzyme (ACE). Studies in rats indicate that lisinopril crosses the blood-brain 
barrier poorly.  
Elimination 
Lisinopril does not undergo metabolism and is excreted entirely unchanged in the urine. On 
multiple dosing lisinopril has an effective half-life of accumulation of 12.6 hours. The 
clearance of lisinopril in healthy subjects is approximately 50 ml/min. Declining serum 
concentrations exhibit a prolonged terminal phase, which does not contribute to drug 
accumulation. This terminal phase probably represents saturable binding to ACE and is not 
proportional to dose.  
Hepatic impairment 
Impairment of hepatic function in cirrhotic patients resulted in a decrease in lisinopril 
absorption (about 30% as determined by urinary recovery) but an increase in exposure 
(approximately 50%) compared to healthy subjects due to decreased clearance.  
Renal impairment 
Impaired renal function decreases elimination of lisinopril, which is excreted via the kidneys, 
but this decrease becomes clinically important only when the glomerular filtration rate is 
below 30 ml/min. In mild to moderate renal impairment (creatinine clearance 30-80 ml/min) 
mean AUC was increased by 13% only, while a 4.5- fold increase in mean AUC was observed 
in severe renal impairment (creatinine clearance 5-30 ml/min).  
Lisinopril can be removed by dialysis. During 4 hours of haemodialysis, plasma lisinopril 
concentrations decreased on average by 60%, with a dialysis clearance between 40 and 55 
ml/min.  
Heart failure 
Patients with heart failure have a greater exposure of lisinopril when compared to healthy 
subjects (an increase in AUC on average of 125%), but based on the urinary recovery of 
lisinopril, there is reduced absorption of approximately 16% compared to healthy subjects.  
Elderly 
Older patients have higher blood levels and higher values for the area under the plasma 
concentration time curve (increased approximately 60%) compared with younger subjects. 
 
5.3 PRECLINICAL  SAFETY  DATA 
Preclinical data reveal no special hazard for humans based on conventional studies of general 
pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Angiotensin 
converting enzyme inhibitors, as a class, have been shown to induce adverse effects on the late 
foetal development, resulting in foetal death and congenital effects, in particular affecting the 
skull. Foetotoxicity, intrauterine growth retardation and patent ductus arteriosus have also 
been reported. These developmental anomalies are thought to be partly due to a direct action 
of ACE inhibitors on the foetal renin-angiotensin system and partly due to ischaemia resulting 
from maternal hypotension and decreases in foetal-placental blood flow and oxygen/nutrients 
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6 PHARMACEUTICAL  PARTICULARS 
6.1  LIST OF EXCIPIENTS 
 Mannitol   
 Calcium  Hydrogen  Phosphate 
  Red Iron Oxide (E172)   
 Maize  Starch   
 Pregelatinised  Starch 
  Colloidal Anhydrous Silica  
Magnesium Stearate 
 
6.2 INCOMPATIBILITIES 
Not applicable. 
 
6.3 SHELF  LIFE 
3 years 
 
6.4 SPECIAL  PRECAUTIONS FOR STORAGE 
Store below 25°C. Store in the original package. 
 
6.5  NATURE AND CONTENTS OF CONTAINER 
PVC / PVDC Aluminium blister packs in a carton in pack sizes of 28 tablets. 
 
6.6 SPECIAL  PRECAUTIONS FOR DISPOSAL 
  No special requirements. 
  Any unused product or waste material should be disposed of in accordance with local 
requirements. 
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SUMMARY OF PRODUCT CHARACTERISTICS 
The UK Summary of Product Characteristics (SPC) for Lisinopril 10mg Tablets is as 
follows: 
 
1  NAME OF THE MEDICINAL PRODUCT 
Lisinopril 10 mg tablets. 
 
2  QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each uncoated tablet contains Lisinopril Dihydrate equivalent to 10 mg of anhydrous 
Lisinopril.  
For a full list of excipients, see section 6.1. 
 
3 PHARMACEUTICAL  FORM 
Tablet 
Pink, round tablets marked ‘10’on one side and scoreline on other side. 
The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal 
doses. 
 
4 CLINICAL  PARTICULARS 
4.1 THERAPEUTIC  INDICATIONS 
Hypertension 
Treatment of hypertension.  
Heart failure 
Treatment of symptomatic heart failure.  
Acute myocardial infarction 
Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an 
acute myocardial infarction.  
Renal complications of diabetes mellitus 
Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient 
nephropathy (see section 5.1).  
 
4.2  POSOLOGY AND METHOD OF ADMINISTRATION 
Lisinopril should be administered orally in a single daily dose. As with all other medication 
taken once daily, Lisinopril should be taken at approximately the same time each day. The 
absorption of Lisinopril tablets is not affected by food.  
The dose should be individualised according to patient profile and blood pressure response 
(see section 4.4).  
Hypertension 
Lisinopril may be used as monotherapy or in combination with other classes of 
antihypertensive therapy.  
Starting dose 
In patients with hypertension the usual recommended starting dose is 10 mg. Patients with a 
strongly activated renin-angiotensin-aldosterone system (in particular, renovascular 
hypertension, salt and /or volume depletion, cardiac decompensation, or severe hypertension) 
may experience an excessive blood pressure fall following the initial dose. A starting dose of 
2.5-5 mg is recommended in such patients and the initiation of treatment should take place 
under medical supervision. A lower starting dose is required in the presence of renal 
impairment (see Table 1 below).  
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Maintenance dose 
The usual effective maintenance dosage is 20 mg administered in a single daily dose. In 
general if the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks on a 
certain dose level, the dose can be further increased. The maximum dose used in long-term, 
controlled clinical trials was 80 mg/day.  
Diuretic-treated patients 
Symptomatic hypotension may occur following initiation of therapy with Lisinopril. This is 
more likely in patients who are being treated currently with diuretics. Caution is recommended 
therefore, since these patients may be volume and/or salt depleted. If possible, the diuretic 
should be discontinued 2 to 3 days before beginning therapy with Lisinopril. In hypertensive 
patients in whom the diuretic cannot be discontinued, therapy with Lisinopril should be 
initiated with a 5 mg dose. Renal function and serum potassium should be monitored. The 
subsequent dosage of Lisinopril should be adjusted according to blood pressure response. If 
required, diuretic therapy may be resumed (see section 4.4 and section 4.5).  
Dosage adjustment In renal impairment 
Dosage in patients with renal impairment should be based on creatinine clearance as outlined 
in Table 1 below.  
Table 1 Dosage adjustment in renal impairment.  
Creatinine Clearance (ml/min)  Starting Dose (mg/day) 
Less than 10 ml/min (including 
patients on dialysis) 
2.5 mg* 
10-30 ml/min  2.5-5 mg 
31-80 ml/min  5-10 mg 
* Dosage and/or frequency of administration should be adjusted depending on the blood 
pressure response.  
The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 
mg daily.  
Heart failure 
In patients with symptomatic heart failure, Lisinopril should be used as adjunctive therapy to 
diuretics and, where appropriate, digitalis or beta-blockers. Lisinopril may be initiated at a 
starting dose of 2.5 mg once a day, which should be administered under medical supervision 
to determine the initial effect on the blood pressure. The dose of Lisinopril should be 
increased:  
•   By increments of no greater than 10 mg  
•   At intervals of no less than 2 weeks  
•   To the highest dose tolerated by the patient up to a maximum of 35 mg once 
 daily   
Dose adjustment should be based on the clinical response of individual patients.  
Patients at high risk of symptomatic hypotension e.g. patients with salt depletion with or 
without hyponatraemia, patients with hypovolaemia or patients who have been receiving 
vigorous diuretic therapy should have these conditions corrected, if possible, prior to therapy 
with Lisinopril. Renal function and serum potassium should be monitored (see section 4.4).  
Acute myocardial infarction 
Patients should receive, as appropriate, the standard recommended treatments such as 
thrombolytics, aspirin, and beta-blockers. Intravenous or transdermal glyceryl trinitrate may 
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Starting dose (first 3 days after infarction) 
Treatment with Lisinopril may be started within 24 hours of the onset of symptoms. Treatment 
should not be started if systolic blood pressure is lower than 100 mm Hg. The first dose of 
Lisinopril is 5 mg given orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and 
then 10 mg once daily. Patients with a low systolic blood pressure (120 mm Hg or less) when 
treatment is started or during the first 3 days after the infarction should be given a lower dose - 
2.5 mg orally (see section 4.4).  
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1).  
Maintenance dose 
The maintenance dose is 10 mg once daily. If hypotension occurs (systolic blood pressure less 
than or equal to 100 mm Hg) a daily maintenance dose of 5 mg may be given with temporary 
reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure less 
than 90 mm Hg for more than 1 hour) Lisinopril should be withdrawn.  
Treatment should continue for 6 weeks and then the patient should be re-evaluated. Patients 
who develop symptoms of heart failure should continue with Lisinopril (see section 4.2)  
Renal complications of diabetes mellitus 
In hypertensive patients with type 2 diabetes mellitus and incipient nephropathy, the dose is 
10 mg Lisinopril once daily which can be increased to 20 mg once daily, if necessary, to 
achieve a sitting diastolic blood pressure below 90 mm Hg.  
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1).  
Paediatric use 
Efficacy and safety of use in children has not been fully established. Therefore, use in children 
is not recommended.  
Use in the elderly 
In clinical studies, there was no age-related change in the efficacy or safety profile of the drug. 
When advanced age is associated with decrease in renal function, however, the guidelines set 
out in Table 1 should be used to determine the starting dose of Lisinopril. Thereafter, the 
dosage should be adjusted according to the blood pressure response.  
Use in kidney transplant patients 
There is no experience regarding the administration of Lisinopril in patients with recent 
kidney transplantation. Treatment with Lisinopril is therefore not recommended.  
 
4.3 CONTRAINDICATIONS 
•   Hypersensitivity to Lisinopril, to any of the excipients or any other angiotensin 
converting enzyme (ACE) inhibitor.  
•   History of angioedema associated with previous ACE inhibitor therapy  
•   Hereditary or idiopathic angioedema.  
•   Second or third trimesters of pregnancy (see section 4.6).  
 
4.4 SPECIAL  WARNINGS AND PRECAUTIONS FOR USE 
Symptomatic hypotension 
Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients. In 
hypertensive patients receiving Lisinopril, hypotension is more likely to occur if the patient 
has been volume-depleted e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea 
or vomiting, or has severe renin-dependent hypertension (see section 4.5 and section 4.8). In 
patients with heart failure, with or without associated renal insufficiency, symptomatic 
hypotension has been observed. This is most likely to occur in those patients with more severe 
degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia UKPAR Lisinopril 2.5mg, 5mg, 10mg & 20mg Tablets  PL 20092/0008-11 
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or functional renal impairment. In patients at increased risk of symptomatic hypotension, 
initiation of therapy and dose adjustment should be closely monitored. Similar considerations 
apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in 
blood pressure could result in a myocardial infarction or cerebrovascular accident.  
If hypotension occurs, the patient should be placed in the supine position and, if necessary, 
should receive an intravenous infusion of normal saline. A transient hypotensive response is 
not a contraindication to further doses, which can be given usually without difficulty once the 
blood pressure has increased after volume expansion.  
In some patients with heart failure who have normal or low blood pressure, additional 
lowering of systemic blood pressure may occur with Lisinopril. This effect is anticipated and 
is not usually a reason to discontinue treatment. If hypotension becomes symptomatic, a 
reduction of dose or discontinuation of Lisinopril may be necessary.  
Hypotension in acute myocardial infarction 
Treatment with Lisinopril must not be initiated in acute myocardial infarction patients who are 
at risk of further serious haemodynamic deterioration after treatment with a vasodilator. These 
are patients with systolic blood pressure of 100 mm Hg or lower or those in cardiogenic 
shock. During the first 3 days following the infarction, the dose should be reduced if the 
systolic blood pressure is 120 mm Hg or lower. Maintenance doses should be reduced to 5 mg 
or temporarily to 2.5 mg if systolic blood pressure is 100 mm Hg or lower. If hypotension 
persists (systolic blood pressure less than 90 mm Hg for more than 1 hour) then Lisinopril 
should be withdrawn.  
Aortic and mitral valve stenosis/hypertrophic cardiomyopathy  
As with other ACE inhibitors, Lisinopril should be given with caution to patients with mitral 
valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or 
hypertrophic cardiomyopathy.  
Renal function impairment 
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1 in section 4.2) 
and then as a function of the patient's response to treatment. Routine monitoring of potassium 
and creatinine is part of normal medical practice for these patients.  
In patients with heart failure, hypotension following the initiation of therapy with ACE 
inhibitors may lead to some further impairment in renal function. Acute renal failure, usually 
reversible, has been reported in this situation.  
In some patients with bilateral renal artery stenosis or with a stenosis of the artery to a solitary 
kidney, who have been treated with angiotensin converting enzyme inhibitors, increases in 
blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been 
seen. This is especially likely in patients with renal insufficiency. If renovascular hypertension 
is also present there is an increased risk of severe hypotension and renal insufficiency. In these 
patients, treatment should be started under close medical supervision with low doses and 
careful dose titration. Since treatment with diuretics may be a contributory factor to the above, 
they should be discontinued and renal function should be monitored during the first weeks of 
Lisinopril therapy.  
Some hypertensive patients with no apparent pre-existing renal vascular disease have 
developed increases in blood urea and serum creatinine, usually minor and transient, 
especially when Lisinopril has been given concomitantly with a diuretic. This is more likely to 
occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation 
of the diuretic and/or Lisinopril may be required.  
In acute myocardial infarction, treatment with Lisinopril should not be initiated in patients 
with evidence of renal dysfunction, defined as serum creatinine concentration exceeding 177 
micromol/l and/or proteinuria exceeding 500 mg/24 h. If renal dysfunction develops during 
treatment with Lisinopril (serum creatinine concentration exceeding 265 micromol/l or a 
doubling from the pre-treatment value) then the physician should consider withdrawal of 
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Hypersensitivity/Angioedema 
Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported 
rarely in patients treated with angiotensin converting enzyme inhibitors, including Lisinopril. 
This may occur at any time during therapy. In such cases, Lisinopril should be discontinued 
promptly and appropriate treatment and monitoring should be instituted to ensure complete 
resolution of symptoms prior to dismissing the patients. Even in those instances where 
swelling of only the tongue is involved, without respiratory distress, patients may require 
prolonged observation since treatment with antihistamines and corticosteroids may not be 
sufficient.  
Very rarely, fatalities have been reported due to angioedema associated with laryngeal oedema 
or tongue oedema. Patients with involvement of the tongue, glottis or larynx, are likely to 
experience airway obstruction, especially those with a history of airway surgery. In such cases 
emergency therapy should be administered promptly. This may include the administration of 
adrenaline and/or the maintenance of a patent airway. The patient should be under close 
medical supervision until complete and sustained resolution of symptoms has occurred.  
Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients 
than in non-black patients.  
Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased 
risk of angioedema while receiving an ACE inhibitor (see section 4.3).  
Anaphylactoid reactions in haemodialysis patients 
Anaphylactoid reactions have been reported in patients dialysed with high flux membranes 
(e.g. AN 69) and treated concomitantly with an ACE inhibitor. In these patients consideration 
should be given to using a different type of dialysis membrane or different class of 
antihypertensive agent.  
Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis 
Rarely, patients receiving ACE inhibitors during low-density lipoproteins (LDL) apheresis 
with dextran sulphate have experienced life-threatening anaphylactoid reactions. These 
reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each 
apheresis.  
Desensitisation 
Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) 
have sustained anaphylactoid reactions. In the same patients, these reactions have been 
avoided when ACE inhibitors were temporarily withheld but they have reappeared upon 
inadvertent re-administration of the medicinal product.  
Hepatic failure 
Very rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic 
jaundice and progresses to fulminant necrosis and (sometimes) death. The mechanism of this 
syndrome is not understood. Patients receiving Lisinopril who develop jaundice or marked 
elevations of hepatic enzymes should discontinue Lisinopril and receive appropriate medical 
follow-up.  
Neutropenia/Agranulocytosis 
Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients 
receiving ACE inhibitors. In patients with normal renal function and no other complicating 
factors, neutropenia occurs rarely. Neutropenia and agranulocytosis are reversible after 
discontinuation of the ACE inhibitor. Lisinopril should be used with extreme caution in 
patients with collagen vascular disease, immunosuppressant therapy, treatment with 
allopurinol or procainamide, or a combination of these complicating factors, especially if there 
is pre-existing impaired renal function. Some of these patients developed serious infections, 
which in a few instances did not respond to intensive antibiotic therapy. If Lisinopril is used in 
such patients, periodic monitoring of white blood cell counts is advised and patients should be 
instructed to report any sign of infection.  
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Race 
Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients 
than in non-black patients.  
As with other ACE inhibitors, Lisinopril may be less effective in lowering blood pressure in 
black patients than in non-blacks, possibly because of a higher prevalence of low-renin states 
in the black hypertensive population.  
Cough 
Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-
productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced 
cough should be considered as part of the differential diagnosis of cough.  
Surgery/Anaesthesia 
In patients undergoing major surgery or during anaesthesia with agents that produce 
hypotension, Lisinopril may block angiotensin II formation secondary to compensatory renin 
release. If hypotension occurs and is considered to be due to this mechanism, it can be 
corrected by volume expansion.  
Hyperkalaemia 
Elevations in serum potassium have been observed in some patients treated with ACE 
inhibitors, including Lisinopril. Patients at risk for the development of hyperkalaemia include 
those with renal insufficiency, diabetes mellitus, or those using concomitant potassium-
sparing diuretics, potassium supplements or potassium-containing salt substitutes, or those 
patients taking other drugs associated with increases in serum potassium (e.g. heparin). If 
concomitant use of the above-mentioned agents is deemed appropriate, regular monitoring of 
serum potassium is recommended (see section 4.5).  
Diabetic patients 
In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should 
be closely monitored during the first month of treatment with an ACE inhibitor (see 4.5 
Interaction with other medicinal products and other forms of interaction).  
Lithium 
The combination of lithium and Lisinopril is generally not recommended (see section 4.5).  
Pregnancy and lactation 
Lisinopril should not be used during the first trimester of pregnancy. Lisinopril is 
contraindicated in the second and third trimesters of pregnancy (see section 4.3). When 
pregnancy is detected, lisinopril treatment should discontinue as soon as possible (see section 
4.6).  
Use of lisinopril is not recommended during breast-feeding. 
 
4.5  INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF 
INTERACTION 
Diuretics 
When a diuretic is added to the therapy of a patient receiving Lisinopril the antihypertensive 
effect is usually additive.  
Patients already on diuretics and especially those in whom diuretic therapy was recently 
instituted, may occasionally experience an excessive reduction of blood pressure when 
Lisinopril is added. The possibility of symptomatic hypotension with Lisinopril can be 
minimised by discontinuing the diuretic prior to initiation of treatment with Lisinopril (see 
section 4.4 and section 4.2).  
Potassium supplements, potassium-sparing diuretics or potassium-containing salt 
substitutes  
Although in clinical trials, serum potassium usually remained within normal limits, 
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include renal insufficiency, diabetes mellitus, and concomitant use of potassium-sparing 
diuretics (e.g. spironolactone, triamterene or amiloride), potassium supplements or potassium-
containing salt substitutes. The use of potassium supplements, potassium-sparing diuretics or 
potassium-containing salt substitutes, particularly in patients with impaired renal function, 
may lead to a significant increase in serum potassium.  
If Lisinopril is given with a potassium-losing diuretic, diuretic-induced hypokalaemia may be 
ameliorated.  
Lithium 
Reversible increases in serum lithium concentrations and toxicity have been reported during 
concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide 
diuretics may increase the risk of lithium toxicity and enhance the already increased lithium 
toxicity with ACE inhibitors. Use of Lisinopril with lithium is not recommended, but if the 
combination proves necessary, careful monitoring of serum lithium levels should be 
performed (see section 4.4).  
Non steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid ≥ 3g/day  
Chronic administration of NSAIDs may reduce the antihypertensive effect of an ACE 
inhibitor. NSAIDs and ACE inhibitors exert an additive effect on the increase in serum 
potassium and may result in a deterioration of renal function. These effects are usually 
reversible. Rarely, acute renal failure may occur, especially in patients with compromised 
renal function such as the elderly or dehydrated.  
Other antihypertensive agents 
Concomitant use of these agents may increase the hypotensive effects of Lisinopril. 
Concomitant use with glyceryl trinitrate and other nitrates, or other vasodilators, may further 
reduce blood pressure.  
Tricyclic antidepressants/Antipsychotics /Anaesthetics 
Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and 
antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see 
section 4.4).  
Sympathomimetics 
Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.  
Antidiabetics 
Epidemiological studies have suggested that concomitant administration of ACE inhibitors 
and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased 
blood glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be 
more likely to occur during the first weeks of combined treatment and in patients with renal 
impairment.  
Acetylsalicylic acid, thrombolytics, beta-blockers, nitrates 
Lisinopril may be used concomitantly with acetylsalicylic acid (at cardiologic doses), 
thrombolytics, beta-blockers and/or nitrates. 
 
4.6 PREGNANCY  AND  LACTATION 
Pregnancy 
Lisinopril should not be used during the first trimester of pregnancy. When pregnancy is 
planned or confirmed the switch to an alternative treatment should be initiated as soon as 
possible. Controlled studies with ACE inhibitors have not been done in humans, but a limited 
number of cases with first trimester toxicity exposure have not appeared to manifest 
malformations consistent with human foetotoxicity as described below.  
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Prolonged ACE inhibitor exposure during the second and third trimesters is known to induce 
human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) 
and neonatal toxicity (renal failure, hypotension, hyperkalaemia (see also section 5.3).  
Should exposure to Lisinopril have occurred from the second trimester of pregnancy, an 
ultrasound check of renal function and the skull is recommended.  
Infants whose mothers have taken Lisinopril should be closely observed for hypotension, 
oliguria and hyperkalaemia. Lisinopril, which crosses the placenta, has been removed from the 
neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be 
removed by exchange transfusion.  
Lactation 
It is not known whether Lisinopril is excreted into human breast milk. Lisinopril is excreted 
into the milk of lactating rats. The use of Lisinopril is not recommended in women who are 
breast-feeding 
 
4.7  EFFECTS ON ABILITY TO DRIVE AND USE MACHINES 
Lisinopril may have a minor or moderate effect on ability to drive and use machines. Patients 
who experience tiredness or dizziness should not drive or use machinery. 
 
4.8 UNDESIRABLE  EFFECTS 
The following undesirable effects have been observed and reported during treatment with 
Lisinopril and other ACE inhibitors with the following frequencies: Very common (≥10%), 
common (≥1%,<10%), uncommon (≥ 0.1, <1%), rare (≥ 0.01, <0.1%), very rare (<0.01%) 
including isolated reports.  
Blood and the lymphatic system disorders:  
rare:     decreases in haemoglobin, decreases in haematocrit.  
very rare:   bone marrow depression, anaemia, thrombocytopenia, leucopenia,  
    neutropenia, agranulocytosis (see section 4.4), haemolytic anaemia,  
  lymphadenopathy,  autoimmune  disease.   
Metabolism and nutrition disorders:  
very rare:   hypoglycaemia.  
 
Nervous system and psychiatric disorders:  
common:   dizziness, headache  
uncommon:   mood alterations, paraesthesia, vertigo, taste disturbance, sleep  
  disturbances.   
rare:     mental confusion.  
Cardiac and vascular disorders:  
common:   orthostatic effects (including hypotension)  
uncommon:   myocardial infarction or cerebrovascular accident, possibly secondary to 
excessive hypotension in high risk patients (see section 4.4), palpitations, 
tachycardia. Raynaud's phenomenon.      
Respiratory, thoracic and mediastinal disorders:  
common:   cough  
uncommon:   rhinitis  
very rare:   bronchospasm, sinusitis. Allergic alveolitis/eosinophilic pneumonia.  
Gastrointestinal disorders:  
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uncommon:   nausea, abdominal pain and indigestion  
rare:     dry mouth  
very rare:   pancreatitis, intestinal angioedema, hepatitis - either hepatocellular or  
    cholestatic, jaundice and hepatic failure (see section 4.4).  
Skin and subcutaneous tissue disorders:  
uncommon:   rash, pruritus  
rare:     hypersensitivity/angioneurotic oedema: angioneurotic oedema of the  
    face, extremities, lips, tongue, glottis, and/or larynx (see section 4.4),  
    urticaria, alopecia, psoriasis.  
very rare:   diaphoresis, pemphigus, toxic epidermal necrolysis, Stevens-Johnson  
  Syndrome,  erythema  multiforme.   
A symptom complex has been reported which may include one or more of the following: 
fever, vasculitis, myalgia, arthralgia/arthritis, a positive antinuclear antibodies (ANA), 
elevated red blood cell sedimentation rate (ESR), eosinophilia and leucocytosis, rash, 
photosensitivity or other dermatological manifestations may occur.  
Renal and urinary disorders:  
common:   renal dysfunction  
rare:     uraemia, acute renal failure  
very rare:   oliguria/anuria.  
Reproductive system and breast disorders:  
uncommon:   impotence  
rare:     gynaecomastia.  
General disorders and administration site conditions:  
uncommon:   fatigue, asthenia.  
Investigations:  
uncommon:   increases in blood urea, increases in serum creatinine, increases in  
    liver enzymes, hyperkalaemia.  
rare:     increases in serum bilirubin, hyponatraemia.  
 
4.9 OVERDOSE 
Limited data are available for overdose in humans. Symptoms associated with overdosage of 
ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal 
failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.  
The recommended treatment of overdose is intravenous infusion of normal saline solution. If 
hypotension occurs, the patient should be placed in the shock position. If available, treatment 
with angiotensin II infusion and/or intravenous catecholamines may also be considered. If 
ingestion is recent, take measures aimed at eliminating Lisinopril (e.g. emesis, gastric lavage, 
administration of absorbents and sodium sulphate). Lisinopril may be removed from the 
general circulation by haemodialysis (see 4.4 special warning and precautions for use). 
Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum 
electrolytes and creatinine concentrations should be monitored frequently.  
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5 PHARMACOLOGICAL  PROPERTIES 
5.1 PHARMACODYNAMIC  PROPERTIES 
Pharmacotherapeutic group: Angiotensin converting enzyme inhibitors, ATC code: C09A 
A03.  
Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin converting enzyme 
(ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, 
angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. 
Inhibition of ACE results in decreased concentrations of angiotensin II which results in 
decreased vasopressor activity and reduced aldosterone secretion. The latter decrease may 
result in an increase in serum potassium concentration.  
Whilst the mechanism through which lisinopril lowers blood pressure is believed to be 
primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is 
antihypertensive even in patients with low renin hypertension. ACE is identical to kininase II, 
an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent 
vasodilatory peptide, play a role in the therapeutic effects of lisinopril remains to be 
elucidated.  
The effect of Lisinopril on mortality and morbidity in heart failure has been studied by 
comparing a high dose (32.5 mg or 35 mg once daily) with a low dose (2.5 mg or 5 mg once 
daily). In a study of 3164 patients, with a median follow up period of 46 months for surviving 
patients, high dose Lisinopril produced a 12% risk reduction in the combined endpoint of all-
cause mortality and all-cause hospitalisation (p = 0.002) and an 8% risk reduction in all-cause 
mortality and cardiovascular hospitalisation (p = 0.036) compared with low dose. Risk 
reductions for all-cause mortality (8%; p = 0.128) and cardiovascular mortality (10%; p = 
0.073) were observed. In a post-hoc analysis, the number of hospitalisations for heart failure 
was reduced by 24% (p=0.002) in patients treated with high-dose Lisinopril compared with 
low dose.Symptomatic benefits were similar in patients treated with high and low doses of 
Lisinopril.  
The results of the study showed that the overall adverse event profiles for patients treated with 
high or low dose Lisinopril were similar in both nature and number. Predictable events 
resulting from ACE inhibition, such as hypotension or altered renal function, were 
manageable and rarely led to treatment withdrawal. Cough was less frequent in patients 
treated with high dose Lisinopril compared with low dose.  
In the GISSI-3 trial, which used a 2x2 factorial design to compare the effects of Lisinopril and 
glyceryl trinitrate given alone or in combination for 6 weeks versus control in 19,394, patients 
who were administered the treatment within 24 hours of an acute myocardial infarction, 
Lisinopril produced a statistically significant risk reduction in mortality of 11% versus control 
(2p=0.03). The risk reduction with glyceryl trinitrate was not significant but the combination 
of Lisinopril and glyceryl trinitrate produced a significant risk reduction in mortality of 17% 
versus control (2p=0.02). In the sub-groups of elderly (age > 70 years) and females, pre-
defined as patients at high risk of mortality, significant benefit was observed for a combined 
endpoint of mortality and cardiac function. The combined endpoint for all patients, as well as 
the high-risk sub-groups, at 6 months also showed significant benefit for those treated with 
Lisinopril or Lisinopril plus glyceryl trinitrate for 6 weeks, indicating a prevention effect for 
Lisinopril. As would be expected from any vasodilator treatment, increased incidences of 
hypotension and renal dysfunction were associated with Lisinopril treatment but these were 
not associated with a proportional increase in mortality.  
In a double-blind, randomised, multicentre trial which compared Lisinopril with a calcium 
channel blocker in 335 hypertensive Type 2 diabetes mellitus subjects with incipient 
nephropathy characterised by microalbuminuria, Lisinopril 10 mg to 20 mg administered once 
daily for 12 months, reduced systolic/diastolic blood pressure by 13/10 mmHg and urinary 
albumin excretion rate by 40%. When compared with the calcium channel blocker, which 
produced a similar reduction in blood pressure, those treated with Lisinopril showed a 
significantly greater reduction in urinary albumin excretion rate, providing evidence that the 
ACE inhibitory action of Lisinopril reduced microalbuminuria by a direct mechanism on renal 
tissues in addition to its blood pressure lowering effect.  
Lisinopril treatment does not affect glycaemic control as shown by a lack of significant effect 
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5.2 PHARMACOKINETIC PROPERTIES 
Lisinopril is an orally active non-sulphydryl-containing ACE inhibitor.  
Absorption 
Following oral administration of lisinopril, peak serum concentrations occur within about 7 
hours, although there was a trend to a small delay in time taken to reach peak serum 
concentrations in acute myocardial infarction patients. Based on urinary recovery, the mean 
extent of absorption of lisinopril is approximately 25% with interpatient variability of 6-60% 
over the dose range studied (5-80 mg). The absolute bioavailability is reduced approximately 
16% in patients with heart failure. Lisinopril absorption is not affected by the presence of 
food.  
Distribution 
Lisinopril does not appear to be bound to serum proteins other than to circulating angiotensin 
converting enzyme (ACE). Studies in rats indicate that lisinopril crosses the blood-brain 
barrier poorly.  
Elimination 
Lisinopril does not undergo metabolism and is excreted entirely unchanged in the urine. On 
multiple dosing lisinopril has an effective half-life of accumulation of 12.6 hours. The 
clearance of lisinopril in healthy subjects is approximately 50 ml/min. Declining serum 
concentrations exhibit a prolonged terminal phase, which does not contribute to drug 
accumulation. This terminal phase probably represents saturable binding to ACE and is not 
proportional to dose.  
Hepatic impairment 
Impairment of hepatic function in cirrhotic patients resulted in a decrease in lisinopril 
absorption (about 30% as determined by urinary recovery) but an increase in exposure 
(approximately 50%) compared to healthy subjects due to decreased clearance.  
Renal impairment 
Impaired renal function decreases elimination of lisinopril, which is excreted via the kidneys, 
but this decrease becomes clinically important only when the glomerular filtration rate is 
below 30 ml/min. In mild to moderate renal impairment (creatinine clearance 30-80 ml/min) 
mean AUC was increased by 13% only, while a 4.5- fold increase in mean AUC was observed 
in severe renal impairment (creatinine clearance 5-30 ml/min).  
Lisinopril can be removed by dialysis. During 4 hours of haemodialysis, plasma lisinopril 
concentrations decreased on average by 60%, with a dialysis clearance between 40 and 55 
ml/min.  
Heart failure 
Patients with heart failure have a greater exposure of lisinopril when compared to healthy 
subjects (an increase in AUC on average of 125%), but based on the urinary recovery of 
lisinopril, there is reduced absorption of approximately 16% compared to healthy subjects.  
Elderly 
Older patients have higher blood levels and higher values for the area under the plasma 
concentration time curve (increased approximately 60%) compared with younger subjects. 
 
5.3 PRECLINICAL  SAFETY  DATA 
Preclinical data reveal no special hazard for humans based on conventional studies of general 
pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Angiotensin 
converting enzyme inhibitors, as a class, have been shown to induce adverse effects on the late 
foetal development, resulting in foetal death and congenital effects, in particular affecting the 
skull. Foetotoxicity, intrauterine growth retardation and patent ductus arteriosus have also 
been reported. These developmental anomalies are thought to be partly due to a direct action 
of ACE inhibitors on the foetal renin-angiotensin system and partly due to ischaemia resulting 
from maternal hypotension and decreases in foetal-placental blood flow and oxygen/nutrients 
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6 PHARMACEUTICAL  PARTICULARS 
6.1  LIST OF EXCIPIENTS 
Mannitol  
Calcium Hydrogen Phosphate 
Red Iron Oxide (E172)   
Maize Starch  
Pregelatinised Starch 
Colloidal Anhydrous Silica  
Magnesium Stearate 
 
6.2 INCOMPATIBILITIES 
Not applicable. 
 
6.3 SHELF  LIFE 
3 years. 
 
6.4 SPECIAL  PRECAUTIONS FOR STORAGE 
Store below 25°C. Store in the original package. 
 
6.5  NATURE AND CONTENTS OF CONTAINER 
PVC / PVDC Aluminium blister packs in a carton in pack sizes of 28 tablets. 
 
6.6 SPECIAL  PRECAUTIONS FOR DISPOSAL 
No special requirements. 
Any unused product or waste material should be disposed of in accordance with local 
requirements. 
 
7 MARKETING  AUTHORISATION HOLDER 
Lupin (Europe) Limited 
Suite 1, Victoria Court, Bexton Road 
Knutsford 
Cheshire WA16 0PF 
United Kingdom 
 
8 MARKETING  AUTHORISATION NUMBER(S) 
PL 20092/0010 
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      20/06/2007 
 
10  DATE OF REVISION OF THE TEXT 
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SUMMARY OF PRODUCT CHARACTERISTICS 
The UK Summary of Product Characteristics (SPC) for Lisinopril 20mg Tablets is as 
follows: 
 
1  NAME OF THE MEDICINAL PRODUCT 
Lisinopril 20 mg tablets. 
 
2  QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each uncoated tablet contains Lisinopril Dihydrate equivalent to 20 mg of anhydrous 
Lisinopril.  
For a full list of excipients, see section 6.1. 
 
3 PHARMACEUTICAL  FORM 
Tablet 
Pink, round tablets marked ‘20’on one side and scoreline on other side. 
The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal 
doses. 
 
4 CLINICAL  PARTICULARS 
4.1 THERAPEUTIC  INDICATIONS 
Hypertension 
Treatment of hypertension.  
Heart failure 
Treatment of symptomatic heart failure.  
Acute myocardial infarction 
Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an 
acute myocardial infarction.  
Renal complications of diabetes mellitus 
Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient 
nephropathy (see section 5.1).  
 
4.2  POSOLOGY AND METHOD OF ADMINISTRATION 
Lisinopril should be administered orally in a single daily dose. As with all other medication 
taken once daily, Lisinopril should be taken at approximately the same time each day. The 
absorption of Lisinopril tablets is not affected by food.  
The dose should be individualised according to patient profile and blood pressure response 
(see section 4.4).  
Hypertension 
Lisinopril may be used as monotherapy or in combination with other classes of 
antihypertensive therapy.  
Starting dose 
In patients with hypertension the usual recommended starting dose is 10 mg. Patients with a 
strongly activated renin-angiotensin-aldosterone system (in particular, renovascular 
hypertension, salt and /or volume depletion, cardiac decompensation, or severe hypertension) 
may experience an excessive blood pressure fall following the initial dose. A starting dose of 
2.5-5 mg is recommended in such patients and the initiation of treatment should take place 
under medical supervision. A lower starting dose is required in the presence of renal 
impairment (see Table 1 below).  
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The usual effective maintenance dosage is 20 mg administered in a single daily dose. In 
general if the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks on a 
certain dose level, the dose can be further increased. The maximum dose used in long-term, 
controlled clinical trials was 80 mg/day.  
Diuretic-treated patients 
Symptomatic hypotension may occur following initiation of therapy with Lisinopril. This is 
more likely in patients who are being treated currently with diuretics. Caution is recommended 
therefore, since these patients may be volume and/or salt depleted. If possible, the diuretic 
should be discontinued 2 to 3 days before beginning therapy with Lisinopril. In hypertensive 
patients in whom the diuretic cannot be discontinued, therapy with Lisinopril should be 
initiated with a 5 mg dose. Renal function and serum potassium should be monitored. The 
subsequent dosage of Lisinopril should be adjusted according to blood pressure response. If 
required, diuretic therapy may be resumed (see section 4.4 and section 4.5).  
Dosage adjustment In renal impairment 
Dosage in patients with renal impairment should be based on creatinine clearance as outlined 
in Table 1 below.  
Table 1 Dosage adjustment in renal impairment.  
Creatinine Clearance (ml/min)  Starting Dose (mg/day) 
Less than 10 ml/min (including 
patients on dialysis) 
2.5 mg* 
10-30 ml/min  2.5-5 mg 
31-80 ml/min  5-10 mg 
* Dosage and/or frequency of administration should be adjusted depending on the blood 
pressure response.  
The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 
mg daily.  
Heart failure 
In patients with symptomatic heart failure, Lisinopril should be used as adjunctive therapy to 
diuretics and, where appropriate, digitalis or beta-blockers. Lisinopril may be initiated at a 
starting dose of 2.5 mg once a day, which should be administered under medical supervision 
to determine the initial effect on the blood pressure. The dose of Lisinopril should be 
increased:  
•   By increments of no greater than 10 mg  
•   At intervals of no less than 2 weeks  
•   To the highest dose tolerated by the patient up to a maximum of 35 mg once 
 daily   
Dose adjustment should be based on the clinical response of individual patients.  
Patients at high risk of symptomatic hypotension e.g. patients with salt depletion with or 
without hyponatraemia, patients with hypovolaemia or patients who have been receiving 
vigorous diuretic therapy should have these conditions corrected, if possible, prior to therapy 
with Lisinopril. Renal function and serum potassium should be monitored (see section 4.4).  
Acute myocardial infarction 
Patients should receive, as appropriate, the standard recommended treatments such as 
thrombolytics, aspirin, and beta-blockers. Intravenous or transdermal glyceryl trinitrate may 
be used together with Lisinopril.  
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Starting dose (first 3 days after infarction) 
Treatment with Lisinopril may be started within 24 hours of the onset of symptoms. Treatment 
should not be started if systolic blood pressure is lower than 100 mm Hg. The first dose of 
Lisinopril is 5 mg given orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and 
then 10 mg once daily. Patients with a low systolic blood pressure (120 mm Hg or less) when 
treatment is started or during the first 3 days after the infarction should be given a lower dose - 
2.5 mg orally (see section 4.4).  
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1).  
Maintenance dose 
The maintenance dose is 10 mg once daily. If hypotension occurs (systolic blood pressure less 
than or equal to 100 mm Hg) a daily maintenance dose of 5 mg may be given with temporary 
reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure less 
than 90 mm Hg for more than 1 hour) Lisinopril should be withdrawn.  
Treatment should continue for 6 weeks and then the patient should be re-evaluated. Patients 
who develop symptoms of heart failure should continue with Lisinopril (see section 4.2)  
Renal complications of diabetes mellitus 
In hypertensive patients with type 2 diabetes mellitus and incipient nephropathy, the dose is 
10 mg Lisinopril once daily which can be increased to 20 mg once daily, if necessary, to 
achieve a sitting diastolic blood pressure below 90 mm Hg.  
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1).  
Paediatric use 
Efficacy and safety of use in children has not been fully established. Therefore, use in children 
is not recommended.  
Use in the elderly 
In clinical studies, there was no age-related change in the efficacy or safety profile of the drug. 
When advanced age is associated with decrease in renal function, however, the guidelines set 
out in Table 1 should be used to determine the starting dose of Lisinopril. Thereafter, the 
dosage should be adjusted according to the blood pressure response.  
Use in kidney transplant patients 
There is no experience regarding the administration of Lisinopril in patients with recent 
kidney transplantation. Treatment with Lisinopril is therefore not recommended. 
 
4.3 CONTRAINDICATIONS 
•   Hypersensitivity to Lisinopril, to any of the excipients or any other angiotensin 
converting enzyme (ACE) inhibitor.  
•   History of angioedema associated with previous ACE inhibitor therapy  
•   Hereditary or idiopathic angioedema.  
•   Second or third trimesters of pregnancy (see section 4.6).  
 
4.4 SPECIAL  WARNINGS AND PRECAUTIONS FOR USE 
Symptomatic hypotension 
Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients. In 
hypertensive patients receiving Lisinopril, hypotension is more likely to occur if the patient 
has been volume-depleted e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea 
or vomiting, or has severe renin-dependent hypertension (see section 4.5 and section 4.8). In 
patients with heart failure, with or without associated renal insufficiency, symptomatic 
hypotension has been observed. This is most likely to occur in those patients with more severe 
degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia UKPAR Lisinopril 2.5mg, 5mg, 10mg & 20mg Tablets  PL 20092/0008-11 
  55
or functional renal impairment. In patients at increased risk of symptomatic hypotension, 
initiation of therapy and dose adjustment should be closely monitored. Similar considerations 
apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in 
blood pressure could result in a myocardial infarction or cerebrovascular accident.  
If hypotension occurs, the patient should be placed in the supine position and, if necessary, 
should receive an intravenous infusion of normal saline. A transient hypotensive response is 
not a contraindication to further doses, which can be given usually without difficulty once the 
blood pressure has increased after volume expansion.  
In some patients with heart failure who have normal or low blood pressure, additional 
lowering of systemic blood pressure may occur with Lisinopril. This effect is anticipated and 
is not usually a reason to discontinue treatment. If hypotension becomes symptomatic, a 
reduction of dose or discontinuation of Lisinopril may be necessary.  
Hypotension in acute myocardial infarction 
Treatment with Lisinopril must not be initiated in acute myocardial infarction patients who are 
at risk of further serious haemodynamic deterioration after treatment with a vasodilator. These 
are patients with systolic blood pressure of 100 mm Hg or lower or those in cardiogenic 
shock. During the first 3 days following the infarction, the dose should be reduced if the 
systolic blood pressure is 120 mm Hg or lower. Maintenance doses should be reduced to 5 mg 
or temporarily to 2.5 mg if systolic blood pressure is 100 mm Hg or lower. If hypotension 
persists (systolic blood pressure less than 90 mm Hg for more than 1 hour) then Lisinopril 
should be withdrawn.  
Aortic and mitral valve stenosis/hypertrophic cardiomyopathy  
As with other ACE inhibitors, Lisinopril should be given with caution to patients with mitral 
valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or 
hypertrophic cardiomyopathy.  
Renal function impairment 
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril dosage 
should be adjusted according to the patient's creatinine clearance (see Table 1 in section 4.2) 
and then as a function of the patient's response to treatment. Routine monitoring of potassium 
and creatinine is part of normal medical practice for these patients.  
In patients with heart failure, hypotension following the initiation of therapy with ACE 
inhibitors may lead to some further impairment in renal function. Acute renal failure, usually 
reversible, has been reported in this situation.  
In some patients with bilateral renal artery stenosis or with a stenosis of the artery to a solitary 
kidney, who have been treated with angiotensin converting enzyme inhibitors, increases in 
blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been 
seen. This is especially likely in patients with renal insufficiency. If renovascular hypertension 
is also present there is an increased risk of severe hypotension and renal insufficiency. In these 
patients, treatment should be started under close medical supervision with low doses and 
careful dose titration. Since treatment with diuretics may be a contributory factor to the above, 
they should be discontinued and renal function should be monitored during the first weeks of 
Lisinopril therapy.  
Some hypertensive patients with no apparent pre-existing renal vascular disease have 
developed increases in blood urea and serum creatinine, usually minor and transient, 
especially when Lisinopril has been given concomitantly with a diuretic. This is more likely to 
occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation 
of the diuretic and/or Lisinopril may be required.  
In acute myocardial infarction, treatment with Lisinopril should not be initiated in patients 
with evidence of renal dysfunction, defined as serum creatinine concentration exceeding 177 
micromol/l and/or proteinuria exceeding 500 mg/24 h. If renal dysfunction develops during 
treatment with Lisinopril (serum creatinine concentration exceeding 265 micromol/l or a 
doubling from the pre-treatment value) then the physician should consider withdrawal of 
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Hypersensitivity/Angioedema 
Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported 
rarely in patients treated with angiotensin converting enzyme inhibitors, including Lisinopril. 
This may occur at any time during therapy. In such cases, Lisinopril should be discontinued 
promptly and appropriate treatment and monitoring should be instituted to ensure complete 
resolution of symptoms prior to dismissing the patients. Even in those instances where 
swelling of only the tongue is involved, without respiratory distress, patients may require 
prolonged observation since treatment with antihistamines and corticosteroids may not be 
sufficient.  
Very rarely, fatalities have been reported due to angioedema associated with laryngeal oedema 
or tongue oedema. Patients with involvement of the tongue, glottis or larynx, are likely to 
experience airway obstruction, especially those with a history of airway surgery. In such cases 
emergency therapy should be administered promptly. This may include the administration of 
adrenaline and/or the maintenance of a patent airway. The patient should be under close 
medical supervision until complete and sustained resolution of symptoms has occurred.  
Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients 
than in non-black patients.  
Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased 
risk of angioedema while receiving an ACE inhibitor (see section 4.3).  
Anaphylactoid reactions in haemodialysis patients 
Anaphylactoid reactions have been reported in patients dialysed with high flux membranes 
(e.g. AN 69) and treated concomitantly with an ACE inhibitor. In these patients consideration 
should be given to using a different type of dialysis membrane or different class of 
antihypertensive agent.  
Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis 
Rarely, patients receiving ACE inhibitors during low-density lipoproteins (LDL) apheresis 
with dextran sulphate have experienced life-threatening anaphylactoid reactions. These 
reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each 
apheresis.  
Desensitisation 
Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) 
have sustained anaphylactoid reactions. In the same patients, these reactions have been 
avoided when ACE inhibitors were temporarily withheld but they have reappeared upon 
inadvertent re-administration of the medicinal product.  
Hepatic failure 
Very rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic 
jaundice and progresses to fulminant necrosis and (sometimes) death. The mechanism of this 
syndrome is not understood. Patients receiving Lisinopril who develop jaundice or marked 
elevations of hepatic enzymes should discontinue Lisinopril and receive appropriate medical 
follow-up.  
Neutropenia/Agranulocytosis 
Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients 
receiving ACE inhibitors. In patients with normal renal function and no other complicating 
factors, neutropenia occurs rarely. Neutropenia and agranulocytosis are reversible after 
discontinuation of the ACE inhibitor. Lisinopril should be used with extreme caution in 
patients with collagen vascular disease, immunosuppressant therapy, treatment with 
allopurinol or procainamide, or a combination of these complicating factors, especially if there 
is pre-existing impaired renal function. Some of these patients developed serious infections, 
which in a few instances did not respond to intensive antibiotic therapy. If Lisinopril is used in 
such patients, periodic monitoring of white blood cell counts is advised and patients should be 
instructed to report any sign of infection.  
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Race 
Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients 
than in non-black patients.  
As with other ACE inhibitors, Lisinopril may be less effective in lowering blood pressure in 
black patients than in non-blacks, possibly because of a higher prevalence of low-renin states 
in the black hypertensive population.  
Cough 
Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-
productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced 
cough should be considered as part of the differential diagnosis of cough.  
Surgery/Anaesthesia 
In patients undergoing major surgery or during anaesthesia with agents that produce 
hypotension, Lisinopril may block angiotensin II formation secondary to compensatory renin 
release. If hypotension occurs and is considered to be due to this mechanism, it can be 
corrected by volume expansion.  
Hyperkalaemia 
Elevations in serum potassium have been observed in some patients treated with ACE 
inhibitors, including Lisinopril. Patients at risk for the development of hyperkalaemia include 
those with renal insufficiency, diabetes mellitus, or those using concomitant potassium-
sparing diuretics, potassium supplements or potassium-containing salt substitutes, or those 
patients taking other drugs associated with increases in serum potassium (e.g. heparin). If 
concomitant use of the above-mentioned agents is deemed appropriate, regular monitoring of 
serum potassium is recommended (see section 4.5).  
Diabetic patients 
In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should 
be closely monitored during the first month of treatment with an ACE inhibitor (see 4.5 
Interaction with other medicinal products and other forms of interaction).  
Lithium 
The combination of lithium and Lisinopril is generally not recommended (see section 4.5).  
Pregnancy and lactation 
Lisinopril should not be used during the first trimester of pregnancy. Lisinopril is 
contraindicated in the second and third trimesters of pregnancy (see section 4.3). When 
pregnancy is detected, lisinopril treatment should discontinue as soon as possible (see section 
4.6).  
Use of lisinopril is not recommended during breast-feeding. 
 
4.5  INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF 
INTERACTION 
Diuretics 
When a diuretic is added to the therapy of a patient receiving Lisinopril the antihypertensive 
effect is usually additive.  
Patients already on diuretics and especially those in whom diuretic therapy was recently 
instituted, may occasionally experience an excessive reduction of blood pressure when 
Lisinopril is added. The possibility of symptomatic hypotension with Lisinopril can be 
minimised by discontinuing the diuretic prior to initiation of treatment with Lisinopril (see 
section 4.4 and section 4.2).  
Potassium supplements, potassium-sparing diuretics or potassium-containing salt 
substitutes  
Although in clinical trials, serum potassium usually remained within normal limits, 
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include renal insufficiency, diabetes mellitus, and concomitant use of potassium-sparing 
diuretics (e.g. spironolactone, triamterene or amiloride), potassium supplements or potassium-
containing salt substitutes. The use of potassium supplements, potassium-sparing diuretics or 
potassium-containing salt substitutes, particularly in patients with impaired renal function, 
may lead to a significant increase in serum potassium.  
If Lisinopril is given with a potassium-losing diuretic, diuretic-induced hypokalaemia may be 
ameliorated.  
Lithium 
Reversible increases in serum lithium concentrations and toxicity have been reported during 
concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide 
diuretics may increase the risk of lithium toxicity and enhance the already increased lithium 
toxicity with ACE inhibitors. Use of Lisinopril with lithium is not recommended, but if the 
combination proves necessary, careful monitoring of serum lithium levels should be 
performed (see section 4.4).  
Non steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid ≥ 3g/day  
Chronic administration of NSAIDs may reduce the antihypertensive effect of an ACE 
inhibitor. NSAIDs and ACE inhibitors exert an additive effect on the increase in serum 
potassium and may result in a deterioration of renal function. These effects are usually 
reversible. Rarely, acute renal failure may occur, especially in patients with compromised 
renal function such as the elderly or dehydrated.  
Other antihypertensive agents 
Concomitant use of these agents may increase the hypotensive effects of Lisinopril. 
Concomitant use with glyceryl trinitrate and other nitrates, or other vasodilators, may further 
reduce blood pressure.  
Tricyclic antidepressants/Antipsychotics /Anaesthetics 
Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and 
antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see 
section 4.4).  
Sympathomimetics 
Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.  
Antidiabetics 
Epidemiological studies have suggested that concomitant administration of ACE inhibitors 
and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased 
blood glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be 
more likely to occur during the first weeks of combined treatment and in patients with renal 
impairment.  
Acetylsalicylic acid, thrombolytics, beta-blockers, nitrates 
Lisinopril may be used concomitantly with acetylsalicylic acid (at cardiologic doses), 
thrombolytics, beta-blockers and/or nitrates. 
 
4.6 PREGNANCY  AND  LACTATION 
Pregnancy 
Lisinopril should not be used during the first trimester of pregnancy. When pregnancy is 
planned or confirmed the switch to an alternative treatment should be initiated as soon as 
possible. Controlled studies with ACE inhibitors have not been done in humans, but a limited 
number of cases with first trimester toxicity exposure have not appeared to manifest 
malformations consistent with human foetotoxicity as described below.  
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Prolonged ACE inhibitor exposure during the second and third trimesters is known to induce 
human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) 
and neonatal toxicity (renal failure, hypotension, hyperkalaemia (see also section 5.3).  
Should exposure to Lisinopril have occurred from the second trimester of pregnancy, an 
ultrasound check of renal function and the skull is recommended.  
Infants whose mothers have taken Lisinopril should be closely observed for hypotension, 
oliguria and hyperkalaemia. Lisinopril, which crosses the placenta, has been removed from the 
neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be 
removed by exchange transfusion.  
Lactation 
It is not known whether Lisinopril is excreted into human breast milk. Lisinopril is excreted 
into the milk of lactating rats. The use of Lisinopril is not recommended in women who are 
breast-feeding. 
 
4.7  EFFECTS ON ABILITY TO DRIVE AND USE MACHINES 
Lisinopril may have a minor or moderate effect on ability to drive and use machines. Patients 
who experience tiredness or dizziness should not drive or use machinery. 
 
4.8 UNDESIRABLE  EFFECTS 
The following undesirable effects have been observed and reported during treatment with 
Lisinopril and other ACE inhibitors with the following frequencies: Very common (≥10%), 
common (≥1%,<10%), uncommon (≥ 0.1, <1%), rare (≥ 0.01, <0.1%), very rare (<0.01%) 
including isolated reports.  
Blood and the lymphatic system disorders:  
rare:     decreases in haemoglobin, decreases in haematocrit.  
very rare:   bone marrow depression, anaemia, thrombocytopenia, leucopenia,  
    neutropenia, agranulocytosis (see section 4.4), haemolytic anaemia,  
  lymphadenopathy,  autoimmune  disease.   
Metabolism and nutrition disorders:  
very rare:   hypoglycaemia.  
 
Nervous system and psychiatric disorders:  
common:   dizziness, headache  
uncommon:   mood alterations, paraesthesia, vertigo, taste disturbance, sleep  
  disturbances.   
rare:     mental confusion.  
Cardiac and vascular disorders:  
common:   orthostatic effects (including hypotension)  
uncommon:   myocardial infarction or cerebrovascular accident, possibly secondary to 
excessive hypotension in high risk patients (see section 4.4), palpitations, 
tachycardia. Raynaud's phenomenon.  
Respiratory, thoracic and mediastinal disorders:  
common:   cough  
uncommon: rhinitis   
very rare:   bronchospasm, sinusitis. Allergic alveolitis/eosinophilic pneumonia.  
Gastrointestinal disorders:  
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uncommon:   nausea, abdominal pain and indigestion  
rare:     dry mouth  
very rare:   pancreatitis, intestinal angioedema, hepatitis - either hepatocellular or  
    cholestatic, jaundice and hepatic failure (see section 4.4).  
Skin and subcutaneous tissue disorders:  
uncommon: rash,  pruritus   
rare:    hypersensitivity/angioneurotic oedema: angioneurotic oedema of the  
    face, extremities, lips, tongue, glottis, and/or larynx (see section 4.4),  
    urticaria, alopecia, psoriasis.  
very rare:   diaphoresis, pemphigus, toxic epidermal necrolysis, Stevens-Johnson  
  Syndrome,  erythema  multiforme.   
A symptom complex has been reported which may include one or more of the following: 
fever, vasculitis, myalgia, arthralgia/arthritis, a positive antinuclear antibodies (ANA), 
elevated red blood cell sedimentation rate (ESR), eosinophilia and leucocytosis, rash, 
photosensitivity or other dermatological manifestations may occur.  
Renal and urinary disorders:  
common:   renal dysfunction  
rare:     uraemia, acute renal failure  
very rare:   oliguria/anuria.  
Reproductive system and breast disorders:  
uncommon:   impotence  
rare:     gynaecomastia.  
General disorders and administration site conditions:  
uncommon:   fatigue, asthenia.  
Investigations:  
uncommon:   increases in blood urea, increases in serum creatinine, increases in  
    liver enzymes, hyperkalaemia.  
rare:     increases in serum bilirubin, hyponatraemia. 
 
4.9 OVERDOSE 
Limited data are available for overdose in humans. Symptoms associated with overdosage of 
ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal 
failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.  
The recommended treatment of overdose is intravenous infusion of normal saline solution. If 
hypotension occurs, the patient should be placed in the shock position. If available, treatment 
with angiotensin II infusion and/or intravenous catecholamines may also be considered. If 
ingestion is recent, take measures aimed at eliminating Lisinopril (e.g. emesis, gastric lavage, 
administration of absorbents and sodium sulphate). Lisinopril may be removed from the 
general circulation by haemodialysis (see 4.4 special warning and precautions for use). 
Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum 
electrolytes and creatinine concentrations should be monitored frequently. 
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5 PHARMACOLOGICAL  PROPERTIES 
5.1 PHARMACODYNAMIC  PROPERTIES 
Pharmacotherapeutic group: Angiotensin converting enzyme inhibitors, ATC code: C09A 
A03.  
Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin converting enzyme 
(ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, 
angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. 
Inhibition of ACE results in decreased concentrations of angiotensin II which results in 
decreased vasopressor activity and reduced aldosterone secretion. The latter decrease may 
result in an increase in serum potassium concentration.  
Whilst the mechanism through which lisinopril lowers blood pressure is believed to be 
primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is 
antihypertensive even in patients with low renin hypertension. ACE is identical to kininase II, 
an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent 
vasodilatory peptide, play a role in the therapeutic effects of lisinopril remains to be 
elucidated.  
The effect of Lisinopril on mortality and morbidity in heart failure has been studied by 
comparing a high dose (32.5 mg or 35 mg once daily) with a low dose (2.5 mg or 5 mg once 
daily). In a study of 3164 patients, with a median follow up period of 46 months for surviving 
patients, high dose Lisinopril produced a 12% risk reduction in the combined endpoint of all-
cause mortality and all-cause hospitalisation (p = 0.002) and an 8% risk reduction in all-cause 
mortality and cardiovascular hospitalisation (p = 0.036) compared with low dose. Risk 
reductions for all-cause mortality (8%; p = 0.128) and cardiovascular mortality (10%; p = 
0.073) were observed. In a post-hoc analysis, the number of hospitalisations for heart failure 
was reduced by 24% (p=0.002) in patients treated with high-dose Lisinopril compared with 
low dose. Symptomatic benefits were similar in patients treated with high and low doses of 
Lisinopril.  
The results of the study showed that the overall adverse event profiles for patients treated with 
high or low dose Lisinopril were similar in both nature and number. Predictable events 
resulting from ACE inhibition, such as hypotension or altered renal function, were 
manageable and rarely led to treatment withdrawal. Cough was less frequent in patients 
treated with high dose Lisinopril compared with low dose.  
In the GISSI-3 trial, which used a 2x2 factorial design to compare the effects of Lisinopril and 
glyceryl trinitrate given alone or in combination for 6 weeks versus control in 19,394, patients 
who were administered the treatment within 24 hours of an acute myocardial infarction, 
Lisinopril produced a statistically significant risk reduction in mortality of 11% versus control 
(2p=0.03). The risk reduction with glyceryl trinitrate was not significant but the combination 
of Lisinopril and glyceryl trinitrate produced a significant risk reduction in mortality of 17% 
versus control (2p=0.02). In the sub-groups of elderly (age > 70 years) and females, pre-
defined as patients at high risk of mortality, significant benefit was observed for a combined 
endpoint of mortality and cardiac function. The combined endpoint for all patients, as well as 
the high-risk sub-groups, at 6 months also showed significant benefit for those treated with 
Lisinopril or Lisinopril plus glyceryl trinitrate for 6 weeks, indicating a prevention effect for 
Lisinopril. As would be expected from any vasodilator treatment, increased incidences of 
hypotension and renal dysfunction were associated with Lisinopril treatment but these were 
not associated with a proportional increase in mortality.  
In a double-blind, randomised, multicentre trial which compared Lisinopril with a calcium 
channel blocker in 335 hypertensive Type 2 diabetes mellitus subjects with incipient 
nephropathy characterised by microalbuminuria, Lisinopril 10 mg to 20 mg administered once 
daily for 12 months, reduced systolic/diastolic blood pressure by 13/10 mmHg and urinary 
albumin excretion rate by 40%. When compared with the calcium channel blocker, which 
produced a similar reduction in blood pressure, those treated with Lisinopril showed a 
significantly greater reduction in urinary albumin excretion rate, providing evidence that the 
ACE inhibitory action of Lisinopril reduced microalbuminuria by a direct mechanism on renal 
tissues in addition to its blood pressure lowering effect.  
Lisinopril treatment does not affect glycaemic control as shown by a lack of significant effect 
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5.2 PHARMACOKINETIC PROPERTIES 
Lisinopril is an orally active non-sulphydryl-containing ACE inhibitor.  
Absorption 
Following oral administration of lisinopril, peak serum concentrations occur within about 7 
hours, although there was a trend to a small delay in time taken to reach peak serum 
concentrations in acute myocardial infarction patients. Based on urinary recovery, the mean 
extent of absorption of lisinopril is approximately 25% with interpatient variability of 6-60% 
over the dose range studied (5-80 mg). The absolute bioavailability is reduced approximately 
16% in patients with heart failure. Lisinopril absorption is not affected by the presence of 
food.  
Distribution 
Lisinopril does not appear to be bound to serum proteins other than to circulating angiotensin 
converting enzyme (ACE). Studies in rats indicate that lisinopril crosses the blood-brain 
barrier poorly.  
Elimination 
Lisinopril does not undergo metabolism and is excreted entirely unchanged in the urine. On 
multiple dosing lisinopril has an effective half-life of accumulation of 12.6 hours. The 
clearance of lisinopril in healthy subjects is approximately 50 ml/min. Declining serum 
concentrations exhibit a prolonged terminal phase, which does not contribute to drug 
accumulation. This terminal phase probably represents saturable binding to ACE and is not 
proportional to dose.  
Hepatic impairment 
Impairment of hepatic function in cirrhotic patients resulted in a decrease in lisinopril 
absorption (about 30% as determined by urinary recovery) but an increase in exposure 
(approximately 50%) compared to healthy subjects due to decreased clearance.  
Renal impairment 
Impaired renal function decreases elimination of lisinopril, which is excreted via the kidneys, 
but this decrease becomes clinically important only when the glomerular filtration rate is 
below 30 ml/min. In mild to moderate renal impairment (creatinine clearance 30-80 ml/min) 
mean AUC was increased by 13% only, while a 4.5- fold increase in mean AUC was observed 
in severe renal impairment (creatinine clearance 5-30 ml/min).  
Lisinopril can be removed by dialysis. During 4 hours of haemodialysis, plasma lisinopril 
concentrations decreased on average by 60%, with a dialysis clearance between 40 and 55 
ml/min.  
Heart failure 
Patients with heart failure have a greater exposure of lisinopril when compared to healthy 
subjects (an increase in AUC on average of 125%), but based on the urinary recovery of 
lisinopril, there is reduced absorption of approximately 16% compared to healthy subjects.  
Elderly 
Older patients have higher blood levels and higher values for the area under the plasma 
concentration time curve (increased approximately 60%) compared with younger subjects. 
 
5.3 PRECLINICAL  SAFETY  DATA 
Preclinical data reveal no special hazard for humans based on conventional studies of general 
pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Angiotensin 
converting enzyme inhibitors, as a class, have been shown to induce adverse effects on the late 
foetal development, resulting in foetal death and congenital effects, in particular affecting the 
skull. Foetotoxicity, intrauterine growth retardation and patent ductus arteriosus have also 
been reported. These developmental anomalies are thought to be partly due to a direct action 
of ACE inhibitors on the foetal renin-angiotensin system and partly due to ischaemia resulting 
from maternal hypotension and decreases in foetal-placental blood flow and oxygen/nutrients 
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6 PHARMACEUTICAL  PARTICULARS 
6.1  LIST OF EXCIPIENTS 
Mannitol  
Calcium Hydrogen Phosphate 
Red Iron Oxide (E172)   
Maize Starch  
Pregelatinised Starch 
Colloidal Anhydrous Silica  
Magnesium Stearate 
 
6.2 INCOMPATIBILITIES 
Not applicable. 
 
6.3 SHELF  LIFE 
3 years. 
 
6.4 SPECIAL  PRECAUTIONS FOR STORAGE 
Store below 25°C. Store in the original package. 
 
6.5  NATURE AND CONTENTS OF CONTAINER 
PVC / PVDC Aluminium blister packs in a carton in pack sizes of 28 tablets. 
 
6.6 SPECIAL  PRECAUTIONS FOR DISPOSAL 
No special requirements. 
Any unused product or waste material should be disposed of in accordance with local 
requirements. 
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PATIENT INFORMATION LEAFLET 
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LABELLING 
Lisinopril 2.5mg Tablets 
Carton for blisters, with braille 
 
 
 
 
Blister foil 
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Lisinopril 5mg Tablets 
Carton for blisters, with braille 
 
 
 
 
 
Blister foil 
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Lisinopril 10mg Tablets 
Carton for blisters, with braille 
 
 
 
 
 
Blister foil 
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Lisinopril 20mg Tablets 
Carton for blisters, with braille 
 
 
 
 
 
Blister foil 
 
 
 
 
 